朝聚眼科
CHAOJU EYE CARE



2025

CHAOJU EYE CARE

Environmental, Social and Governance Report

CONTENTS

About This Report 01

Board Statement 03

About Chaoju Eye Care 04

Company Profile 04

01. Standardized Operation and Strengthened Corporate Governance

- Corporate Governance 07
- ESG Management 09
- Risk Management and Internal Control 13
- Business Ethics 14

02. Serving Patients and Improving Medical Quality

- Medical Quality Management 17
- Assurance of Medical Safety 20
- Medical Service Management 23
- Pharmaceutical Quality Management 26
- Scientific Research and Innovation 28

03. Upholding Responsibility to Achieve Stable Operations

- Responsible Marketing 35
- Supply Chain Management 36
- Information Security and Patient Privacy Protection 37

04. Prioritising Employees and Cultivating a Harmonious Workplace

- Employee Employment 41
- Employee Rights and Benefits 42
- Employee Communication 43
- Employee Training 43
- Employee Incentives and Promotion 46
- Occupational Health and Work Safety 47

05. Cherishing the Environment and Fostering Green Development

- Resource Management 51
- Emissions Management 53
- Climate Change Response 54


06. Passing Love and Engaging in Charitable Actions

- Volunteer Medical Consultation and Vision Screening 59
- Enhancing Ophthalmic Diagnosis and Treatment Capacity Development 61
- Eye Health Knowledge Dissemination 63

Annex I: Quantitative ESG Data Table 65

Annex II: Index Table of The Hong Kong Stock Exchange's ESG Reporting Code 70





About This Report

This report is the fifth *Environmental, Social and Governance Report* released by Chaoju Eye Care Holdings Limited that aims to provide stakeholders such as regulators and investors with a comprehensive understanding of the Company's ESG practices and achievements.

Scope of the Report

The scope of this report covers Chaoju Eye Care Holdings Limited and its subsidiaries (hereinafter referred to as "Chaoju Eye Care", "the Group", and "the Company"). Unless expressly indicated otherwise, the scope of this report is consistent with that of the consolidated financial statements of the corresponding period of Chaoju Eye Care (stock code: 02219).

List of Company Names and Abbreviations Used in This Report

Full company name	Abbreviation used in this report
Baotou City Chaoju Eye Hospital Co., Ltd.	Baotou Hospital
Baotou City Kunlun Chaoju Eye Hospital Co., Ltd.	Baotou Kunlun Hospital
Chengde Chaoju Eye Hospital Co., Ltd.	Chengde Hospital
Hulunbuir Chaoju Eye Hospital Co., Ltd.	Hulunbuir Hospital
Hohhot Chaoju Eye Hospital Co., Ltd.	Hohhot No.2 Hospital
Xiangshan Chaoju Eye Hospital Co., Ltd.	Xiangshan Hospital

Note: The table above lists only the subsidiaries and affiliated hospitals mentioned in the report, and is not the complete list of subsidiaries of Chaoju Eye Care.

Reporting Period

This report covers the period from January 1, 2025 to December 31, 2025. Certain content extends appropriately beyond this timeframe to enhance comparability and completeness.

Basis of the Report

This report is prepared in accordance with the *Environmental, Social and Governance Reporting Code* (the "ESG Reporting Code") in Appendix C2 to the *Main Board Listing Rules* of the Hong Kong Stock Exchange. An index of the prepared content is provided in the appendix of this report.

Report Preparation Principles

This report is prepared in accordance with the four principles of "Materiality", "Quantitative", "Balance" and "Consistency".

Materiality

This report focuses on material issues of concern to stakeholders such as investors, taking into account industry and regional characteristics, while providing detailed disclosure on environmental, social and governance (ESG) matters with significant impact. For the analysis process and results of the material issues, please refer to "About Chaoju Eye Care" herein.

Quantitative

In accordance with the ESG Reporting Code, this report follows applicable quantitative standards and practices, adopts quantitative methods to measure and disclose relevant key performance indicators (KPIs) and sets environmental targets that include actual figures and directional statements. The measurement standards, methods, hypotheses and/or calculation tools used for KPIs in this report, as well as the sources of conversion factors, have been explained where applicable.

Balance

This report reflects objective facts and discloses both positive and negative information about the Company in an unbiased manner.

Consistency

This report is prepared in consistency with the methodologies of previous years. Where changes have been made that may affect meaningful comparison with previous reports, these changes have been described in the corresponding sections.

Sources and Reliability Assurance

The cases and data presented in this report are derived from official records utilized by the Company. Some of the data are extracted from the 2025 Annual Report, while other data originate from the Company's internal systems or manual records. The Company confirms that this report contains no false records or misleading statements, and takes full responsibility for the authenticity, accuracy, and completeness of its content.

Access to the Report

This report is disclosed in digital format, and is accessible on the Hong Kong Stock Exchange's designated information disclosure platform (http://www.hkexnews.hk/) and via the Company's official website (http://www.chaojueye.com/) for online reading or download.

Contact Us

In case of any suggestions regarding this report, please feel free to contact us:

Address: Room 2403, East Zone Block A, Capital Tech Plaza, No. 14 Yard, West 3rd Ring South Road, Fengtai District, Beijing, China

Email: ir@chaojueye.com

Board Statement

The Board of Directors assumes ultimate responsibility for Chaoju Eye Care's ESG governance and strategy. The Group has established an ESG governance framework and management processes, with regular reporting on ESG-related matters to the Board.

Chaoju Eye Care attaches great importance to the significant impact that ESG risks may have on the Company and has integrated them into the risk management system. The Group assesses the materiality of various ESG issues through methods such as ESG risk identification and communication with internal and external stakeholders. The Board participates in the evaluation, prioritization, and management of material ESG issues, oversees the assessment of ESG-related risks and opportunities, defines the key focus areas for the Group's ESG governance, and regularly reviews ESG management strategies.The Group has established environmental targets linked to its business operations. The Board of Directors and the Audit Committee review and evaluate the establishment and progress of these targets during their annual meetings.

This report provides a comprehensive disclosure of environmental, social, and governance matters and has been reviewed and approved by the Board of Directors on March 31, 2026.



About Chaoju Eye Care

Company Profile

Chaoju Eye Care, inaugurated in Baotou, Inner Mongolia in 1988, is a leading ophthalmic medical service group in Northern China with a strong reputation nationwide. Since the establishment, Chaoju Eye Care has demonstrated unwavering commitment and dedication to providing patients with safe, effective, and patient-friendly ophthalmic medical services. Through 37 years of deep expertise in the industry, Chaoju Eye Care has built a service network of eye hospitals and optical centers spanning seven provincial-level regions. Committing to the vision of "Being a Leader of Happy Ophthalmic Healthcare", Chaoju Eye Care become a nationally recognized ophthalmic medical services group, supported by professional and effective medical technology, high-quality patient care, and advanced medical equipment. The Group was listed on the Main Board of the Hong Kong Stock Exchange in July 2021 (Stock Code: 2219.HK).

The Group provides medical services such as consumer ophthalmic services and basic ophthalmic services, along with eye health-related pharmaceutical products, leveraging a high-level professional medical team and advanced, effective equipment and technology. The Group maintains a continuous focus on the development of eye health. By the end of the Reporting Period, the Group operates a network consisting of 31 ophthalmic hospitals and 32 optical centers, spanning seven provinces, municipalities and autonomous regions across China, meeting patient needs with high-quality medical services.

Main Business and Layout

Consumer ophthalmic services	Treatments and prevention of various types of ophthalmic disorders, including refractive correction (including presbyopia correction), myopia control, dry eye syndrome, ocular plastic surgery and provision of optical products and services.
Basic ophthalmic services	Treatments of a wide range of common eye diseases, including cataract, glaucoma, squint, ocular fundus diseases, ocular surface diseases, orbital diseases and pediatric eye diseases.

01 |

Standardized Operation and Strengthened Corporate Governance

- Corporate Governance
- Risk Management and Internal Control
- ESG Management
- Business Ethics




Standardized Operation and Strengthened Corporate Governance

Corporate Governance

Governance Framework

The Company strictly abides by the *Cayman Islands Companies Act*, the *Company Law of the People's Republic of China*, the *Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited* and other relevant laws and regulations, and has formulated the *Memorandum and Articles of Association of Chaoju Eye Care Holdings Limited* (hereinafter referred to as the *Articles of Association*), the *Terms of Reference of the Nomination Committee of the Board of Directors of Chaoju Eye Care Holdings Limited*, the *Terms of Reference of the Remuneration Committee of the Board of Directors of Chaoju Eye Care Holdings Limited* and the *Terms of Reference of the Audit Committee of the Board of Directors of Chaoju Eye Care Holdings Limited*, and other management systems. Besides, the Company has also established a corporate governance framework composed of the shareholders' meeting, the Board of Directors and its special committees and management. This framework forms a governance mechanism characterized by a clear division of responsibilities, mutual coordination, and checks and balances, ensuring efficient and compliant corporate governance.

Corporate Governance Framework



Board Diversity


The Group has adopted and implemented the *Board Diversity Policy* to ensure that the selection of board candidates is based on diversity indicators, including but not limited to professional experience, skills, knowledge, gender, age, cultural and educational background, ethnicity, and length of service. The Nomination Committee oversees the implementation of the Board Diversity Policy and reviews it periodically to ensure its continued effectiveness.

By the end of the Reporting Period, the Board of Directors consists of 11 members, including four executive directors, three non-executive directors and four independent non-executive directors, with a total of three female directors. The Board members possess extensive knowledge and experience in fields such as clinical medicine, public healthcare, business management, financial management, finance, economics, accounting and law. This diversity of expertise supports the Board in making optimal decisions and promotes the Company's sustainable and healthy development. For details on the professional backgrounds of the Board members, please refer to the *2025 Annual Report*.


By the end of the Reporting Period

the Board of Directors consists of **11** members including **4** executive directors, **3** non-executive directors and **4** independent non-executive directors


Function Composition of the Board of Directors



Age Demographics of the Board of Directors



Gender Demographics of the Board of Directors




ESG Management

ESG Management Vision and Strategy

Adhering to the vision of "Being a Leader of Happy Ophthalmic Healthcare", the Group continued to focus on development and value growth in the ophthalmology sector and identified six key areas related to our own operational development. Moreover, we have established the ESG strategy and promoted the implementation of the Group's ESG management to ensure the high-quality development of the Group.

Key Areas of ESG Management



ESG Governance Structure

The Group attaches great importance to ESG management. We have formulated the *Environmental and Social Responsibility Management System*, and built a top-down three-level ESG governance structure and management mechanism to standardize ESG governance and continuously improve ESG performance. As the highest decision-making level, the Board of Directors is responsible for reviewing the ESG strategies and supervising major risks. The ESG Committee, led by the Board of Directors, is responsible for formulating ESG policies, overseeing risks and promoting the achievement of goals. Each department of the Group and its subordinate units are responsible for the specific implementation and reporting to ensure that ESG efforts are integrated into daily operations.

ESG Governance Structure

Responsibility Subject	Duties
Board of Directors	• Review ESG strategies, goals, and business integration paths • Make decisions on major ESG risks • Review externally disclosed ESG information (e.g., reports, statements) • Assess progress against ESG goals, with a focus on achieving "zero incidents" in occupational health and safety, improving energy and water efficiency, and optimizing waste and emissions intensity • Analyze the impact of ESG performance on medical service quality, operational efficiency and cost control
ESG Committee	• Develop and review ESG issues and strategies, prioritize ESG issues • Identify and oversee potential ESG risks in daily operations (including risks to the Group's business) • Approve the disclosure of the annual ESG report, etc. • Develop ESG goals, including occupational health and safety, energy management, water resource management, emissions management, and response to climate change, and regularly review and evaluate progress towards these goals
Departments at headquarters, affiliated hospitals and optical centers	• Manage and implement ESG work within their respective responsibilities • Report ESG work to the Board of Directors

Stakeholder Communication

The Company issued a total of **56** announcements

The Group strictly complies with the laws and regulations of its operating locations, as well as the requirements of the Securities and Futures Commission of Hong Kong and the Stock Exchange of Hong Kong. On this basis, we have established internal policies such as the *Regulations on Information Disclosure Affairs* and the *Internal Information Transmission Management System*. Through channels including strategy meetings, investor relations email, and WeChat groups, the Group proactively and promptly discloses information that may significantly influence the decisions of shareholders and other stakeholders. This enhances the transparency of the Company's operations and management and fully safeguards the legitimate rights and interests of investors. During the Reporting Period, the Company issued a total of 56 announcements.

While enhancing information disclosure, we have established diverse communication mechanisms and channels with stakeholders. Through platforms such as our website, media engagements and meetings, we regularly understand and respond to their expectations and concerns. We integrate the key issues raised by stakeholders, including shareholders, investors, patients, government and regulatory authorities, employees, suppliers, and the community, into the Company's operational and decision-making processes. This approach enables us to continuously improve overall management standards and sustainable development capabilities.

Stakeholder Communication

Key Stakeholders	Issues of Concern		Communication Modes	
Shareholders and Investors	• Corporate governance • Business ethics	• Risk management • Research and innovation	• Shareholders' meeting • Anti-corruption training • Announcements and circulars	• Financial reports • Journal articles
Patients	• Medical service management • Medical quality and safety • Information security and privacy protection	• Research and innovation • Access to medical services	• Patient consultation and complaint handling • "One doctor, one patient" service paradigm	• Journal articles • Volunteer medical consultation and vision screening
Government and Regulatory Authorities	• Compliance operations • Business ethics • Medical service management	• Medical quality and safety • Pharmaceutical quality management • Response to climate change	• Participation in regulatory meetings and correspondence • Anti-corruption training	• Signing of *Anti-Commercial Bribery and Anti-Fraud Agreement* • Patient consultation and complaint handling • Medical quality enhancement training
Employees	• Human capital development • Employee rights and benefits	• Occupational health and safety	• Employee training system • Internal training and expatriate learning	• Employee care • Monitoring of occupational hazards
Suppliers	• Supply chain management • Compliance operations	• Business ethics • Medical quality and safety	• Supplier evaluations and routine communication • Signing of *Anti-Commercial Bribery and Anti-Fraud Agreement*	• Anti-corruption training
Communities and Public	• Emissions management • Resource management	• Access to medical services • Community and public welfare	• Volunteer medical consultation and vision screening • Dissemination of health education	

Material Issue Identification

The Group has followed the "Materiality Principle" outlined in the Environmental, Social and Governance Reporting Guide issued by The Stock Exchange of Hong Kong Limited ("SEHK") and, based on its own business and operational characteristics, conducted a materiality issues analysis.


Material Issue Analysis Procedure

Identify
- Analyze Chinese macro policies and industry news;
- Summarize and analyze the ESG Reporting Code of the SEHK and other standards;
- Analyze the Company's strategic orientation, business undertakings, and practical emphases to pinpoint pertinent issues.

Communicate and sort
- Conduct materiality analysis based on the communication with internal stakeholders and the opinions of external experts;
- Evaluate issues based on expert analysis results and their importance in terms of impact on the economy, environment, society, and stakeholders.

Analyze and report
- Rank issues by importance based on the evaluation results to construct a materiality matrix;
- Review and validate issues of high materiality by the Board of Directors, and disclose these issues in annual ESG reports.

Materiality Matrix




External Honors and Recognition

- Chaoju Eye Care was honored with the 2025 "ESG Model Enterprise – Special Contribution Award for the 'Belt and Road Initiative'" by Guancha.cn
- Chaoju Eye Care was selected on the 2025 "Future Power" Leading Enterprises List by Stockstar
- Chaoju Eye Care had a total of 112 academic achievements successfully selected for presentation at the 29th National Ophthalmology Congress of the Chinese Medical Association (CCOS 2025).
- The Director of the Discipline Construction Committee of Chaoju Eye Care was awarded the title of "2025 Inner Mongolia Autonomous Region Model Worker"
- Chaoju (Inner Mongolia) Eye Hospital Co., Ltd. and Baotou City Chaoju Eye Hospital Co., Ltd. ("Baotou Hospital") were rated as "Grade-A Tertiary Specialized Hospitals", and Chaoju (Chifeng) Eye Hospital Co., Ltd. ("Chifeng Hospital") was rated as "Grade-B Tertiary Specialized Hospital"
- Ulanqab Chaoju Eye Hospital was awarded the title of "National Civilized Unit"
- Hangzhou Chaoju Eye Hospital was selected as a member of the "China Ophthalmic Technology Innovation Science Popularization Alliance "
- Baotou Hospital was awarded the title of "Leading High-Efficiency Growth Enterprise"
- Chifeng Hospital was awarded the title of "Integrity Demonstration Enterprise"
- Tongliao Chaoju Eye Hospital was recognized as a "Special Contribution Enterprise for Graduate Employment of Tongliao Vocational College" and as an "Industry-Education Integration Training Base"

Risk Management and Internal Control

The Group has established a sound risk management procedure, requiring all relevant departments to conduct necessary risk identification, assessment and analysis within the scope of their duties, and perform their responsibility of risk control.



The Group adheres to a risk management-oriented approach, strictly complying with the *Corporate Governance Code* and other regulatory requirements. The Group has developed the *Management System for Decision-making on Major Matters* and the *Audit Rectification Management Measures*, which clearly define the responsible parties and their duties for audit rectification, rectification procedures, methods, assessment, accountability, and penalties, establishing an internal control system to regulate the Group's business and investment activities and enhance overall risk prevention capabilities.

Each year, the Group evaluates its internal control through self-inspections, checks, tests, verifications, interviews, and discussions. Combined with internal audits of subsidiaries and optical centers, the Group evaluates its business management and control and confirms whether there are any internal control deficiencies within the evaluation scope. During the Reporting Period, no significant internal control deficiencies were identified. During the Reporting Period, the Board of Directors has reviewed the effectiveness of the Group's risk management and internal control systems and considers them to be effective and adequate.



Business Ethics

The Group strictly complies with the laws and regulations of its operating locations, including the *Criminal Law of the People's Republic of China*, the *Anti-Unfair Competition Law of the People's Republic of China*, the *Anti-Money Laundering Law of the People's Republic of China*, and the *Nine Principles of Honest Practice of Medical Institution Staff*. The Group has formulated the *Measures for the Administration of Anti-Fraud Work* and the *Notice on the Code of Professional Ethics for Group Medical Personnel*, establishing a comprehensive business ethics management framework. The framework clearly define the division of responsibilities for business ethics management and regulate the professional conduct of all directors and employees across the Group.

Anti-Corruption Management

Chaoju Eye Care maintains zero tolerance for any behavior that violates business ethics, resolutely opposing corruption, bribery, money laundering, unfair competition, fraud, and conflicts of interest. We have integrated anti-corruption risks into our overall risk management processes. During the Reporting Period, the Group carried out 12 special audits, departure, and operational audits. The audits covered areas such as medical income and costs, procurement and payments, financial management, capital, and human resources. All issues identified during the audits have been rectified.

We continuously strengthen internal business ethics development through training, seminars, and informational materials, delivering business ethics education to all employees, including Board members. This initiative guides all employees in establishing correct values, cultivating integrity and ethical professional standards, and fostering a healthy corporate culture and positive work environment.

In the area of tendering and procurement management, the Group adheres to the principles of establishing systems first, standardizing processes, clarifying responsibilities, and conducting supervision throughout. All procurement activities are strictly executed in accordance with the Group's current procurement management systems to ensure compliance, traceability, and credibility. To prevent conflicts of interest and integrity risks at the source, the Group clearly defines the authority and responsibility boundaries for each stage, including demand initiation, procurement organization, expert evaluation, and result approval, achieving division of responsibilities, mutual checks, and mutual oversight. The Group signs *Anti-Commercial Bribery and Anti-Fraud Agreements* with all suppliers and issues *Letters of Notification on Integrity and Self-Discipline* to reinforce awareness of integrity in cooperation. In addition, we regularly organize anti-corruption and integrity self-discipline training for procurement personnel from both the group and our hospitals, continuously reinforcing internal compliance awareness and strengthening the defense line against integrity risks.

Whistleblowing and Protection Mechanism

Company employees and external parties who have direct or indirect business relationships with the Company may report information regarding violations of professional ethics by employees, as well as actual or suspected fraud cases, through various channels such as hotlines, email, or written correspondence. After receiving a report, the Audit and Supervision Department shall promptly register it and create a case record. For reports that require investigation, an investigation will be initiated based on the circumstances, and accountability will be pursued.

We place great importance on protecting the privacy of complainants and whistleblowers, prohibiting any illegal discrimination, retaliation, or hostile actions against employees involved in investigations. Any personnel who violate this, by disclosing complaint or whistleblower information or retaliating against complainants or whistleblowers, will be subject to appropriate administrative penalties, up to and including termination of employment. Cases that constitute criminal offenses will be referred to judicial authorities for processing.

During the Reporting Period, the Group did not experience any incidents of corruption, bribery, extortion, fraud, or money laundering. No corruption litigation cases against the Group or its employees were filed and concluded.

02 |

Serving Patients and Improving Medical Quality

- Medical Quality Management
- Pharmaceutical Quality Management
- Assurance of Medical Safety
- Scientific Research and Innovation
- Medical Service Management



Serving Patients and Improving Medical Quality

Medical Quality Management

The Group strictly abides by the laws and regulations such as the Law on Licensed Doctors of the People's Republic of China, the Regulation on the Administration of Medical Institutions, the *Medical Quality Management Measures* and other national laws and regulations. We consistently uphold the "patient-centered" service philosophy and are committed to delivering high-quality medical services. During the year, we formulated and updated internal systems such as the *Measures for the Administration of Law-Based Practice of Medical Institutions of the Group*, the *Measures for the Assessment and Administration of Medical Insurance Payment of the Group*, and the *Measures for the Administration of Hierarchical Authorization of Surgeries of the Group*. These measures clarify standardized practice procedures, refine medical insurance payment assessment management, and establish an early warning mechanism for medical dispute risk compensation, thereby comprehensively enhancing the standardization and safety of our medical services.

During the year, we further implemented the *Regional Medical Quality Management Implementation Scheme*, establishing a regionalized management mechanism based on the existing medical quality management framework. Four major regions were designated in Eastern Inner Mongolia, Western Inner Mongolia, Jiangsu-Zhejiang, and Shanxi-Hebei-Inner Mongolia. Each region is equipped with dedicated quality leads and part-time quality management personnel, forming a four-tier quality management system comprising the "Group–Region–Hospital–Department" levels. Within this framework, the Group is responsible for formulating systems and overseeing assessments; the regions are responsible for overall coordination and implementation supervision; while hospitals and departments are responsible for specific execution and continuous improvement, achieving an integration of standardized management and differentiated implementation. This structure enables the integration of standardized management with differentiated implementation. In addition, we have established a Medical Quality Control Committee comprising both internal and external experts, which undertakes responsibilities including technical support, quality control decision-making, and quality assessment.

Medical Quality Inspection Mechanism

In 2025, the Group established a multi-dimensional supervision mechanism encompassing "daily inspections, quarterly review and notifications, continuous tracking, and annual assessment and evaluations" to strengthen full-process management of medical quality. For hospitals failing to meet quality standards or exhibiting prominent risk concerns, as well as those involved in medical disputes or facing high-risk complaints, targeted on-site supervision and follow-up guidance were implemented. Additionally, a regional coordination mechanism was activated, where the Group's Medical Quality Department collaborated with regional leads to intervene on-site and assist in resolving risk incidents. Common medical quality issues were regularly aggregated and analyzed to drive systemic optimization and management improvements across the Group. Furthermore, whenever hospitals encountered complex challenges in daily medical quality management, they could consult the Group's Medical Quality Department or regional quality leads at any time to obtain professional guidance and handling recommendations.

Medical Quality Inspection Mechanism

The Group's Medical Quality Department

Conduct biannual onsite medical quality inspections across all hospitals, providing onsite guidance on identified issues and ensuring continuous follow-up.

Regional Medical Quality Management Staff

Conduct quarterly on-site medical quality inspections, providing onsite guidance on identified issues and ensuring continuous follow-up, and reporting findings to the Group's Medical Quality Department.

Hospital Leadership

Conduct monthly on-site medical quality inspections, providing immediate guidance on identified issues and ensuring continuous follow-up; conduct quarterly medical quality analysis, and reporting findings to both regional departments and the Group.

Case National Ophthalmology Professional Medical Quality Control Center

To fully implement the National Health Commission's requirements on strengthening medical quality management and to systematically advance the nationwide assessment of ophthalmology medical quality, in August 2025, professional institutions including the National Ophthalmology Professional Medical Quality Control Center and Zhongshan Ophthalmic Center of Sun Yat-sen University visited Hulunbuir Hospital to investigate the quality of ophthalmic medical work. During the visit, the experts conducted on-site inspections of various diagnostic and treatment areas of the hospital, inquired in detail about the allocation of medical equipment, technical proficiency of personnel, diagnostic and treatment processes, and the implementation of medical quality control measures across departments. This visit provided Hulunbuir Hospital with valuable guidance and development directions. We will draw upon this visit as an opportunity to earnestly implement all recommendations put forward by the experts, continuously enhancing the quality of our medical services, and providing safer, more effective, and patient-friendly ophthalmic care for the people of the Hulunbuir region and the Inner Mongolia Autonomous Region as a whole.



During the Reporting Period, the Group did **not experience** any major group complaints or repeated complaint incidents.

Medical Quality Culture Development

In 2025, with the core theme of "quality-first, patient-centered", the Group systematically advanced the medical quality culture development. We established a comprehensive medical quality training system that covers all employees and is implemented across different levels. For medical personnel, routine training on medical service quality and safety was conducted regularly. For medical quality management personnel, specialized training sessions were organized monthly on a regional basis, covering modules such as policy and system interpretation, and quality analysis. During the year, we conducted over 80 training sessions, reaching more than 2,000 participants, with a qualification rate exceeding 90% and a 100% pass rate. Additionally, we published a "Monthly Newsletter on Medical Quality", implemented special initiatives for medical quality and safety, and conducted four cultural analyses focusing on employee belonging, frontier exploration and innovation, quality standard optimization, and enhancement of humanistic care. Simultaneously, we drafted the *Fundamental Principles of Medical Quality Culture* to effectively strengthen awareness of medical quality across all employees and solidify the foundation of medical quality management.

We conducted over

80 training sessions

reaching more than

2,000 participants

with a qualification rate exceeding

90%

and


100% pass rate

We have established a medical quality incentive mechanism, introducing annual assessment awards such as the Advanced Collective Award for Comprehensive Assessment of Medical Quality Management, the Medical Quality Management Improvement Award, Best Cataract Surgery Quality Award, Best Cataract Surgery Technique Award, and Special Individual Award for Medical Quality Management. These awards reward hospitals and individuals that meet standards, driving continuous improvement in medical quality.

Intractable Disease Treatment

During the year, the Group formulated the *Implementation Plan for the Intractable Diseases Consultation Center* and revised the *Intractable Cases Discussion System* to standardize the consultation and discussion processes for intractable cases, promote interdisciplinary and inter-physician communication, and enhance the clinical diagnostic capabilities of medical personnel. We have also established a Difficult Diseases Consultation Center to match expert resources according to needs, and remote consultation centers to expand the coverage of high-quality medical services and safeguard the eye health of more patients.

In 2025, we established a Group-level database and management system for intractable disease categories, enabling information-based management of intractable cases. We also compiled a *Collection of Typical Intractable Case Analysis* for internal learning, exchange, and knowledge transfer. Monthly multi-disciplinary discussions (MDT) on intractable cases were organized, bringing together experts from various hospitals for collective analysis, thereby helping medical employees stay abreast of industry advancements. During the Reporting Period, the overall medical quality level of the Group remained stable and showed positive improvement.



Assurance of Medical Safety

Management of Medication Safety

The Group strictly abides by the *Drug Administration Law of the People's Republic of China*, the *Pharmacopoeia of the People's Republic of China 2020*, and associated legal and regulatory frameworks, and has formulated the *Drug Administration Measures*, the *Management System for High-Risk Drugs*, the *Adverse Drug Reaction Monitoring and Reporting System*, the *Special Drug Management System*, the *Adverse Drug Reaction Monitoring System*, the *Management System for Safe Use of Drugs*, the *Management and Monitoring System for the Clinical Use of Antimicrobial Agents*. This establishes a systematic framework for drug usage and storage, strengthens the hierarchical management of antimicrobial drugs and prescription reviews, promotes the application of rational drug use information systems, and enables pre-prescription automated review and medication risk alerts.

Rational Drug Use Management System

Chaoju Eye Care has established a rational drug use management system and conducts routine prescription review work. We organize our subordinate hospitals to perform monthly specialized reviews of prescriptions for medications such as antibiotics, pediatric medications, and glucocorticoids, with the relevant data and results regularly consolidated and reported.

Key Medication Usage Indicators

Key Indicators	2025 Data
Pathogen testing rate before antibiotic treatment for inpatients	87.9%
Prophylactic antibiotic use rate for Class I incision surgeries	8.32%
Prescription rationality rate	≥98% (continuously optimizing)

Management of Medical Device Safety

The Group strictly abides by the *Regulations on the Supervision and Administration of Medical Devices*, the *Medicinal Product Administration Law of the People's Republic of China*, the *Interim Regulations on the Administration of Pharmaceutical Affairs in Medical Institutions*, and other relevant laws and regulations. We have developed internal management documents such as the *Charter for the Pharmaceutical and Medical Device Management Committee* and the *Detailed Rules for Pharmaceutical and Medical Device Management* to ensure the safe management of medical devices.

Regarding the utilization of medical devices, the Group is committed to selecting premium medical supplies and reviewing supplier qualifications, including the business licenses of suppliers, medical device operation permits, manufacturers' business licenses, production record licenses, record certificates, registration certificates for medical devices, and health permits for disinfection product manufacturers to assure the safety and reliability of medical devices.

Hospital Infection Prevention and Control Mechanism

The Group has established a four-tier organizational framework for hospital infection management, comprising the "Infection Management Committee of the Group's Medical Department, Hospital-acquired Infection Management Committee, Hospital Infection Control Department, and Departmental Infection Control Team", standardizing the management of hospital-acquired infections from top to bottom. During the Reporting Period, the Group further advanced hospital infection prevention and control to a more systematic and standardized system. We revised eight management systems in accordance with the latest national standards and organized specialized training for all employees. We established an ophthalmology-specific quality control indicator system for hospital-acquired infections, continuously implementing the closed-loop management of "monitoring – analysis – rectification – review". We adopted a "dual random inspections + key hospital supervision" model, strengthening on-site guidance and follow-up rectification of infection control issues. We also carried out regular activities including hand hygiene promotion and special inspections on environmental surface cleaning, so as to comprehensively enhance the awareness of hospital-acquired infection prevention and control among all employees.


Hospital-Acquired Infection Training

Trainee	Training Frequency and Content
Newly recruited medical, nursing, and technical staff	• The training on basic knowledge of hospital-acquired infection is carried out every six months.
Medical and nursing technicians, laborers, marketers and other personnel	• Comprehensive management knowledge of hospital-acquired infection is carried out once a month including hand hygiene, medical waste, disinfection and isolation.
Care workers, cleaners, security guards and other personnel	• Training is carried out every six months to help employees strengthen their own protection and improve the hospital-acquired infection prevention and control capabilities.

Management of Medical Quality Adverse Events

The Group has fortified the management of medical safety adverse events and standardized the event reporting based on the *Ten Patient Safety Goals* issued by the China Hospital Association. During the year, we revised management documents such as the *Medical Safety (Adverse) Event Reporting and Management System* to achieve closed-loop management of adverse events across the entire process.





The Group has established a graded management system for medical safety adverse events. Under this system, Level I and Level II events must be reported, while reporting of Level III and Level IV events is encouraged. All incidents are handled strictly in accordance with established procedures. We mandate that root cause analysis be conducted for all adverse events of Level II or higher, and have established a closed-loop mechanism for monthly analysis, notification, feedback, and follow-up. During the Reporting Period, the Group recorded 49 Level II or higher adverse events. All these incidents were investigated, managed, rectified, and provided with feedback following the prescribed processes. None resulted in long-term adverse effects on patients or led to significant medical disputes or litigation.

We have updated the core objectives for medical service safety, implemented real-time monitoring of key indicators through an information technology platform, and incorporated these indicators into hospital performance evaluations.

2025 Medical Service Quality and Safety Goals and Progress

Annual goals	Result	
Mortality rate for low-risk conditions: 0%	0%	(Achieved)
Surgical site infection rate for Class I incisions: ⩽ 0.1%	0.001%	(Achieved)
Incidence of infectious endophthalmitis: 0%	0%	(Achieved)
Medical safety adverse event reporting rate: ⩾ 2.5 cases per 100 persons	3.10 cases per 100 persons	(Achieved)


Medical Service Management

Medical Service Management and Optimization

To improve the quality of medical services, the Group has developed various system documents such as the *Annual Service Quality Management Evaluation Guidelines*, the *Patient Return Visit System*, the *Hospital Complaint Management System*, the *Medical Dispute Prevention and Management Measures*, and the *Service Adverse Event Management System*, the *Image Management Standard List*, and the *Customer Service Management System*, all of which regulate medical service processes and provide patients with high-quality services throughout their entire journey, from admission, consultation, pre-operation to post-operation.

Clearly display and publicize the outpatient and inpatient processes to ensure that every patient understands the steps for medical treatment; The guidance desk and service windows, including both manual and self-service kiosks, follow strict service standards.

Professional medical personnel provide guidance and accompany patients for examinations as needed, ensuring the smooth progress of the examination process.



During their hospital stay, patients' physical condition and psychological needs are closely monitored. For patients whose birthdays occur during their stay, small gifts are provided as a gesture of care.

Regular post-discharge follow-up services are provided to stay informed of the patients' recovery progress and offer necessary guidance and advice.

Effective communication with patients is carried out before and after surgery. Additionally, tools such as stress-relief balls are provided to help alleviate pre- and post-surgery tension and anxiety; A comprehensive pain management plan is in place after surgery, which includes patient education and the use of necessary pain relief measures to ensure patient comfort.

Detailed discharge education is provided to patients upon discharge, including important information on post-operative care and follow-up visits.

Chaoju Eye Care has continued to advance its 9S Meticulous Management and Service Augmentation, cumulatively driving the implementation and successful acceptance of 19 hospitals across Inner Mongolia, Baotou, Chifeng, Ulanqab, and other locations. Significant improvements have been achieved in equipment and facilities, wayfinding signage, corporate culture walls, and other areas at each hospital. Targeted renovations have been carried out in line with the distinctive characteristics of individual hospitals, effectively enhancing departmental work efficiency, optimizing the patient care experience, and better satisfying patients' diverse needs in terms of comfort, safety, spiritual well-being, and aesthetic appeal.

Cumulatively driving the implementation and successful acceptance of

19 hospitals

The Group conducted a total of

21 training sessions for hospital staff on topics

With the core objective of "zero service complaints," the Group actively promotes the continuous optimization of service quality at each hospital in light of actual conditions. Through the annual service quality assessment, we systematically examine the service status of each hospital, covering dimensions including service processes, service management, complaint handling, and patient satisfaction. This enables us to identify common issues, jointly explore solutions with hospitals, and monitor and supervise the implementation and effectiveness of corrective measures.

During the Reporting Period, service leaders from each hospital convened meetings to collectively summarize and analyze service highlights and issues, clarifying management requirements. Meanwhile, the Group launched the "Happy Action Service Plan," requiring service leaders at each hospital to assist the hospital president in providing "happy service" to patients in consumer ophthalmology, completing the *Summer Service Recommendations* to support action planning, and collecting and compiling related initiatives from each hospital. In addition, the Group conducted a total of 21 training sessions for hospital staff on topics including image management standards, service quality improvement, service culture development, and existing service issues, enhancing employees' service awareness and capabilities.

To respond to and address patient concerns in a timely manner, the Group has established a grading mechanism for medical service adverse events, categorizing incidents into Level I to Level IV, with corresponding management requirements developed for each level. Specifically, Level I and Level II incidents must be reported, while reporting of Level III and Level IV incidents is encouraged. The Group handles all reported incidents promptly, continuously improving and enhancing the quality of medical services.

Medical Service Adverse Event

Level I

- Extremely poor service attitude, verbal abuse, or physical and verbal conflicts with patients, causing mental or physical harm to patients (or their families), leading to severe negative impact, including disputes, and damage to the hospital's reputation.

Level II

- Poor service attitude, evasion, indifference, rude language, or confrontational behavior towards patients (or their families), leading to disputes or escalation of the situation, resulting in patient complaints.

Level III

- Discontent (complaints) from patients (or their families) due to environmental factors, deficiencies in the medical process, inadequate service, or unintentional errors by staff during service.

Level IV

- Poor communication between medical staff and patients, or patients (or their families) being dissatisfied with the treatment outcomes.

Patient Complaint Management

The Group has formulated a series of internal policies, including the *Patient Return Visit System* and the *Hospital Complaint Management System*, in accordance with laws and regulations such as the *Measures for the Administration of Medical Quality*. A systematic patient complaint handling process has been established to ensure that issues are followed up, resolved, and improved. Upon receiving a complaint, immediate coordination and resolution will be provided if it can be handled on the spot. If it cannot be resolved on the spot, the hospital's customer service department will record and verify the complaint, and transfer it to the relevant department for handling based on the category of the issue. The handling result will be fed back to the patient by the customer service department. Afterwards, the customer service department will report the situation to the Group's Customer Service Department, and report adverse events in accordance with regulations. We also employ diversified channels such as telephone, on-site reception, WeChat public accounts, and the president's mailbox to comprehensively understand patients' evaluations of hospital services, collect opinions and suggestions, and identify directions for service optimization.

During the Reporting Period, the Group implemented unified telephone return visits for outpatient and myopia prevention and control patients to gain in-depth understanding of their postoperative experiences. If a patient is dissatisfied with the surgical outcome, the case will be directly transferred to the relevant hospital, where the doctors will conduct a second return visit and provide professional guidance. If a patient is dissatisfied with the service, we will assess the responsible unit in accordance with relevant management measures to continuously improve patient satisfaction.

In terms of medical dispute prevention, the Group has formulated the *Medical Dispute Prevention and Management Measures* in accordance with laws and regulations such as the *Regulations on the Prevention and Handling of Medical Disputes*, so as to reduce the possibility of medical disputes from the source. For example, for diagnosis and treatment activities involving risks such as surgery and invasive procedures, we require medical personnel to fully explain the risks to patients in advance. In the event of a dispute, emergency response plans will be immediately activated. The medical dispute handling team will organize experts to conduct responsibility identification and assessment, and provide corresponding economic compensation to patients when necessary.

2025 Patient Complaints and Patient Satisfaction Survey Results

Complaints	63
Ratio of complaint handled	100%

Specialty follow-ups

Contacted	Effective response to	Average satisfaction rate of
8,723 individuals	2,752 individuals	99.13%

Outpatient follow-ups

Contacted	Effective response to	Satisfaction rate of
52,174 individuals	16,541 individuals	98.04%

Pharmaceutical Quality Management

Full-Process Management of Pharmaceutical Formulation

Baotou Hospital, one of the Group's subsidiaries, is the only ophthalmic hospital in Inner Mongolia with a preparation room. Baotou Hospital produces traditional Chinese medicine capsules and eye drops and is one of the few service providers in China that can produce 0.01% atropine sulphate eye drops prescribed by relevant hospitals for the prevention and control of myopia in adolescents.

Baotou Hospital's preparation room strictly adheres to the *Drug Administration Law of the People's Republic of China*, the *Pharmacopoeia of the People's Republic of China (2020 Edition)*, and other relevant laws and regulations. The hospital has developed the *Standard Management Procedure for Batch Quality Evaluation and Release in Preparation Room*, the *Standard Operating Procedure for Handling Unqualified Materials in Preparation Room*, and the *Standard Operating Procedure for Handling Unqualified Finished Products in Preparation Room*, establishing a quality management system that covers the entire lifecycle of pharmaceuticals, from raw and auxiliary materials, and packaging materials, intermediate products, to finished products.

Full-Process Pharmaceutical Quality Management Measures

Raw and auxiliary materials, and packaging materials

- Check the completeness and accuracy of relevant documents, and verify whether the supplier is an approved supplier;
- Verify the consistency of product names, batch numbers, and quantities in the inspection records and inspection reports;
- Implement current quality standards and inspection operating procedures, including manufacturer's inspection reports, packaging integrity, and sealing checks, and provide clear quality evaluation conclusions.

Intermediate products

- Strictly follow production processes and standard operating procedures to ensure accurate material input without cross-contamination;
- Adhere to quality standards and inspection procedures, ensure the records are reviewed and accurate, and that inspection results meet quality standards;
- Quality evaluation of intermediate products must have clear conclusions; products are only released if they meet the required standards. Non-conforming products should be appropriately handled.

Finished products

- Random sampling and inspection of finished products are conducted during production to ensure product quality;
- Perform quality evaluations for each batch of medicine before release, ensuring that products and their production comply with registration and regulatory requirements;
- After reviewing production and quality records and confirming they are qualified, the medicines can be put into use.

Pharmaceutical Adverse Reaction Management

The Group places great importance on pharmaceutical safety. In accordance with the *Drug Administration Law of the People's Republic of China*, the *Regulations on the Administration of Pharmaceutical Affairs in Medical Institutions*, and the *Regulations on the Administration of Narcotic Drugs and Class 1 Psychotropic Substances in Medical Institutions*, the Group has developed management policies such as the *Drug Administration Measures*, the *Management System for High Risk Drugs*, and the *Management System for Safe Use of Drugs*, which covers the entire process from procurement and storage to dispensing, thereby ensuring the safety of medications for every patient. In addition, we comply with the relevant provisions on labeling stipulated in the *Regulations for the Implementation of the Drug Administration Law of the People's Republic of China*, conducting meticulous review and standardized production of drug label content to ensure accurate communication of medication information.

We adhere to the principle of "Quality First, Needs-Based Procurement, and Selective Sourcing" to ensure the quality of medications and the legality of procurement activities. We have established a "patient-centered" operational model to enhance rational drug use and strengthen medication safety. The Group continuously improves the monitoring and reporting mechanism for adverse drug reactions (ADR). During the Reporting Period, no severe or cluster ADR incidents occurred.


During the year, Baotou Hospital actively conducted a series of training activities focusing on drug quality management and operational protocols. These activities covered updates in laws and regulations, operational procedures, and professional standards, with the aim of enhancing staff professional competence and operational compliance.

Product Recall and Management of Expired Pharmaceuticals

In compliance with the Regulations for the Implementation of the Drug Administration Law of the People's Republic of China and the Drug Recall Management Measures, the Group has comprehensively upgraded its product recall management system, refined the graded management of drug recalls, and specified recall timelines, providing clear requirements for hospitals to promptly identify and properly handle non-conforming pharmaceuticals. When receiving urgent pharmaceutical recall notices, the hospitals under the Group can respond promptly, recall the designated products as required, and store them in specified locations. After verification and confirmation, the recalled drugs are destroyed by designated personnel with complete documentation. During the Reporting Period, the percentage of products sold or shipped that required recall for safety or health reasons was zero, and no litigation arose from such issues.

Additionally, to ensure pharmaceutical quality and standardized management, the Group's subsidiaries have developed management systems for handling products nearing expiration or those that have degraded or become ineffective. For instance,

To further strengthen the management of expired pharmaceuticals, the Group's subsidiaries have shifted their approach from passive disposal to proactive prevention and control. At the system level, a dual control mechanism of "First In, First Out" and "Priority Outbound for Products Nearing Expiry" has been implemented through digital means. At the institutional level, each subsidiary has established dedicated management systems. For instance, Chengde Hospital established the *Pharmaceutical Return Management System*, and Baotou Kunlun Hospital established the *Management System for Expired and Degraded Pharmaceuticals*, which clarify procedures for return and exchange of non-conforming products, enhance early warning management for products nearing expiry, standardize destruction procedures for expired/ineffective products, thereby achieving closed-loop management of the entire drug lifecycle to ensure patient medication safety from the source.



Scientific Research and Innovation

Discipline Construction Development

Discipline construction serves as the cornerstone of the Company and its business development. Under the leadership of the Chief Operating Officer as the highest-level supervisor, we have established a three-tier disciplinary management framework comprising the Discipline Construction Committee, the Discipline Construction Office, and the hospital chief medical officers. This framework oversees ten professional sub-groups, including Cataract, Refractive, and Glaucoma, to systematically advance our work.

Disciplinary Management Framework

Discipline Construction Committee

- Responsible for the Company's discipline construction and development plans, organising the formulation and updating of policies, reviewing decisions related to discipline development, organising academic and research activities, reviewing and guiding the development goals and talent training plans for each hospital, researching and resolving key issues in discipline construction, and inspecting, supervising and assessing progress.

Discipline Construction Office and professional sub-groups

- The Discipline Construction Office is responsible for the daily tasks authorised by the Discipline Construction Committee.
- The professional sub-groups are primarily responsible for the development planning of their respective specialties, the formulation of technical standards or guidelines, talent cultivation, professional training, and the promotion of new technologies.

Hospital chief medical officers and leaders of each professional discipline

- Hospital chief medical officers are fully responsible for implementing hospital disciplinary planning, construction, and management, coordinating to resolve systemic issues hindering discipline development, motivating professionals within the discipline, and assisting with discipline evaluations, inspections, and assessments.
- Leaders of each professional discipline are responsible for the sub-goals of discipline construction.

The Group has implemented management policies such as the *Discipline Construction Management System*, the *Academic Scientific Research Paper System*, the *Scientific Research Project Application and Approval System*, and the *Clinical Scientific Research Management System*, ensuring the scientific, standardised, and efficient development of disciplines, thereby enhancing the Group's overall research capability and academic influence. In terms of talent development, we optimise departmental staffing and focus on strengthening the systematic training and cultivation of attending physicians and postgraduate students. We actively deepen our collaborations with universities and colleges, driving progress in both academic and research fields to enhance the quality of talent cultivation. We continuously refine our talent development mechanism, reasonably plan the number of national-level research projects, strengthen the leadership role of hospital presidents as discipline leaders, create conditions for doctors to undertake research tasks, and foster interdisciplinary integration to cultivate and discover well-rounded talent through innovative practice.

Furthermore, the Group has established and continuously refined its scientific research incentive mechanism, providing corresponding cash rewards for outstanding papers, publications, and scientific research projects completed by hospitals, research groups, or individuals. This aims to stimulate the enthusiasm and creativity of researchers, driving the continuous development and innovative breakthroughs of the Group's scientific research endeavors.

Discipline Construction Direction

Focus on Strengthening Construction Units

- Strengthen the development of the Refractive Surgery Centre
- Establish a Presbyopia Centre and carry out presbyopia correction
- Expand Traditional Chinese Medicine Ophthalmology services
- Develop digital systems for myopia prevention and control

Accelerate Standardised Construction and Technological Innovation

- Improve standardised SOPs to guide and regulate the diagnosis and treatment procedures for common diseases within each academic group
- Establish a Remote Consultation Centre and improve organizational structure and standardised procedures
- Enhance the construction of the eye bank by improving the cornea donation process, standardising cornea processing and preservation procedures, and surgical protocols

Develop Specialised Disciplines

- Assist the operations department in planning and developing key departments and specialised units across the Group's hospitals.

The Group has continuously improved its scientific research platform construction. In 2025, the Group regularly invited experts to hold 2 sessions of clinical research training courses, improving clinicians' clinical research capabilities through thematic lectures, practical demonstrations, face-to-face guidance, and post-class follow-up tutoring. The Group also completed the conclusion of 5 Group-level scientific research projects.

The Group also completed the conclusion of

5 Group-level scientific research projects





The Group actively plans its future research and development blueprint, continually expanding the breadth and depth of research fields. Clear and challenging short- and medium-term goals have been set in four areas: research, papers, patents, and awards, with the aim of achieving major breakthroughs in key technologies and frontier fields.

Research Goals and Progress

Category	Goals for 2030	Progress in 2025
Research	3-5 national-level projects more than 5-8 provincial-level projects more than 10 municipal-level projects	1 national-level project 2 provincial-level projects 3 municipal-level projects
Papers	100 core journal papers, 50 SCI papers	15 core journal papers and SCI papers
Patents	50 Patents	10 Patents
Awards	3-5 Awards	1 Award

Intellectual Property Protection

The Group strictly complies with the *Civil Code of the People's Republic of China*, *Patent Law of the People's Republic of China*, *Trademark Law of the People's Republic of China*, *Copyright Law of the People's Republic of China*, and other relevant laws and regulations. We standardise our own intellectual property management and avoid infringement of others' intellectual property, enhancing the awareness of intellectual property protection among all employees.

The Group actively carries out the registration, renewal, and maintenance of its own trademarks, effectively protects the copyright of the "Big Eye Meng" software, promotes the standardised implementation of the Chaoju Eye Care brand visual identity system, and achieves full-cycle control of brand intangible assets. During the Reporting Period, the Group registered two new trademarks, duly authorising their use by its hospitals and optical centers. The Group did not incur any penalties from relevant authorities for infringing the intellectual property of others.

Industry Communication and Collaboration

Chaoju Eye Care fosters collaboration through platform development and connects resources via industry exchanges, accelerating the transformation of research outcomes and technological innovation. The Group established the Centre for the Promotion of Applicable Traditional Chinese Medicine Techniques at Chaoju (Inner Mongolia) Eye Hospital, initiating an innovative cooperation model between public and private hospitals across regions and building a solid platform for promoting applicable TCM techniques in ophthalmology. Chaoju (Inner Mongolia) Eye Hospital will also integrate resources with the Eye Hospital of the China Academy of Chinese Medical Sciences to continuously carry out activities such as skill training, academic exchanges, and research collaboration, advancing the clinical application of applicable TCM techniques. Furthermore, we have signed a cooperation agreement with Peking University Third Hospital to enhance the development of ophthalmology disciplines and talent cultivation across all levels of medical institutions, with the goal of better serving patients at the grassroots level.

We actively participates in industry association activities and hosts numerous academic meetings, as well as seminars for promoting new technologies and projects, to enhance communication and exchanges within the industry. During the Reporting Period, the Group cumulatively hosted 27 various academic meetings.

Case "Light on the Sea" Exhibition

In January 2025, the "Light on the Sea" Exhibition grandly opened in Shanghai, where industry peers gathered to discuss cutting-edge trends and groundbreaking achievements in the field of ophthalmic healthcare. Representatives from Chaoju Eye Care comprehensively presented the company's developmental journey, future blueprint, and talent strategy, while also sharing the Group's valuable experience and unique insights in the ophthalmic medical field. This participation not only demonstrated our professional strength in the ophthalmic medical field but also strengthened exchanges and collaboration both within and beyond the industry. In the future, Chaoju Eye Care will continue to uphold its brand philosophy of "Using safe, effective, and friendly services to promote the joy of eye health for humanity" and provide high-quality medical services to more patients.



Case Launch Ceremony for Chaoju Eye Care's Artificial Intelligence Strategy and the AI Ophthalmologist System

In June 2025, the Launch Ceremony for Chaoju Eye Care's Artificial Intelligence Strategy and the AI Ophthalmologist System was grandly held in Beijing. The event focused on "Doctor Zhang Mulan," an AI-powered intelligent agent product developed by Chaoju Eye Care, which is dedicated to the field of eye health as a digital diagnostic and treatment assistant. "Doctor Zhang Mulan" is already capable of providing full-process assistance in ophthalmic diagnosis and treatment, including conducting medical consultation, generating outpatient medical records, and offering preliminary diagnoses and treatment plans. It not only adjusts medication recommendations based on the latest guidelines but also lists multiple possible differential diagnoses for complex cases. Additionally, it assists junior doctors in paying attention to details that may be overlooked during diagnosis and treatment, further enhancing the safety and precision of care.

Looking ahead, Chaoju Eye Care is committed to enabling "Doctor Zhang Mulan" to become the world's first empirically validated ophthalmologist intelligent agent within two years, possessing capabilities in clinical practice, scientific research, teaching, health education, preventive care, and assisting in public health and medical insurance policy management. This initiative aims to pioneer a new paradigm for collaborative healthcare in the future.



Case The 9th Academic Annual Meeting of the Ophthalmology Professional Committee of the Chinese Non-Governmental Medical Institutions Association & National Clinical Ophthalmology Annual Meeting

In July 2025, the 9th Academic Annual Meeting of the Ophthalmology Professional Committee of the Chinese Non-Governmental Medical Institutions Association & National Clinical Ophthalmology Annual Meeting, hosted by Chaoju Eye Care, was held in Hohhot. With the theme "AI Leads the Way: New Transformation of Intelligent Diagnosis and Treatment in Non-Governmental Ophthalmology," the meeting featured 14 thematic forums, including sessions on fundus diseases, cataracts, surgical videos and complex case surgical videos, ophthalmic imaging & artificial intelligence, and AI-focused panels. The content covered all aspects of ophthalmic clinical practice. Through in-depth exchanges and discussions at this annual meeting, experts, scholars, and industry practitioners in the field of ophthalmology reached greater consensus on the application of AI technology, disciplinary development, and clinical practices. This injected new vitality and momentum into the intelligent and high-quality development of non-governmental ophthalmology, jointly driving China's ophthalmic medical cause to new heights and bringing more hope and well-being to the vast number of patients with eye diseases.



Case Chaoju Eye Care Dry Eye Product Launch & The 7th Joint Meeting of the Corneal Disease Subgroup

In August 2025, the "Caring for Eyes, Enlightening the World – 2025 Chaoju Eye Care Dry Eye Product Launch & The 7th Joint Meeting of the Corneal Disease Subgroup" was successfully held. Centered on the themes of "technological innovation, academic discourse, standard co-creation, and ecosystem resonance," the conference attracted top domestic institutions and ophthalmic elites from multiple regions, offering a comprehensive showcase of cutting-edge breakthroughs in the diagnosis, treatment, and prevention of dry eye and corneal diseases. The event also marked the official announcement of the full-scale launch of Chaoju Eye Care's OEM dry eye diagnosis and treatment products, signifying a new stage in the Group's capabilities within the dry eye care supply chain and industrialization.



The Group continues to deepen school-enterprise cooperation and jointly build talent cultivation bases integrating industry and education. Since October 2020, driven by a shared vision of cultivating optometry professionals, Chaoju Eye Care and Baotou Medical College have engaged in in-depth collaboration in areas such as talent cultivation and scientific research innovation. Both parties remain committed to their fundamental mission of "cultivating talents for the Party and the nation," working together to create a high-quality platform for the development of optometry professionals and achieving the goal of " promoting medicine through education and assisting education through medical practice."

Case Environment and Health Artificial Intelligence Collaborative Innovation Center

In June 2025, Chaoju Eye Care, in collaboration with Beijing Institute of Technology, jointly established the "Environment and Health Artificial Intelligence Collaborative Innovation Center." This initiative leverages technology to empower research and break down data barriers, serving as an integrated platform that fosters interdisciplinary collaboration within the university and promotes synergy with external partners. The unveiling of this center marks a significant breakthrough in the Group's strategy of integrating industry, academia, and research. By partnering with universities to build innovative platforms, we accelerate the application and transformation of AI technologies in areas such as cataract, fundus diseases, myopia prevention and control, and environmental factor analysis for dry eye syndrome, thereby advancing our corporate vision of "Being a Leader of Happy Ophthalmic Healthcare."




During the Reporting Period, the Group participated in the development of standards such as the *Standards for Preoperative Imaging and Electrophysiological Examination in Vitreoretinal Surgery* and the *Standards for Common Imaging Examinations in Orbital Diseases*, leveraging its professional expertise to contribute to the standardized development of the industry.

03 |

Upholding Responsibility to Achieve Stable Operations

- Responsible Marketing
- Information Security and Patient Privacy Protection
- Supply Chain Management



Upholding Responsibility to Achieve Stable Operations

Responsible Marketing

The Group's promotional activities obey relevant regulations, including the *Advertising Law of the People's Republic of China*, the *Measures for the Administration of Medical Advertisements*, the *Measures for the Administration of Internet Advertising*, the *Measures for Penalizing Infringements of Consumer Rights and Interests*, the *Guidelines for Identifying Medical Advertisements*, and the *Regulations on Standardizing Medical Science Communication by "Self-Media" Platforms*. The Group has established internal policies for reviewing and disseminating promotional content, forming a comprehensive responsible marketing system to ensure that all external communications are truthful, accurate, and compliant.

We consistently adhere to the principles of authenticity, accuracy, timeliness, and compliance. In accordance with the business and diagnostic scope approved in the business license and the medical institution practice license, we complete the filing of the Medical Advertisement Approval Form and use the filed content of this form as the basis for review, ensuring that all marketing and promotional activities are carried out in a lawful and compliant manner.

Advertising and Content Promotion Review Management Process



The Group maintains a "zero-tolerance" policy toward the dissemination of unapproved false or misleading information. Once identified, we will impose appropriate penalties on the relevant personnel in accordance with internal management regulations, based on the severity of the circumstances. Should the dissemination of inaccurate information lead to consumer complaints, claims, or harm to the Group's brand reputation, the involved individuals will bear corresponding legal liabilities and compensate the Group for any resulting losses.

The Group conducts responsible marketing training for promotional, marketing, and customer service personnel through various methods, including theoretical explanations, practical exercises, and offline instruction. These training sessions focus on strengthening compliance, authenticity, and accuracy in information dissemination, ensuring that all external communications adhere to legal and ethical standards. During the Reporting Period, no reviewed and approved content incurred any regulatory penalties due to false advertising, misleading marketing, or violations of advertising regulations.

Case Transfer Training for Quality Courses from DXY (DingXiangYuan)

To enhance the professional capabilities and compliance standards of our teams, the Group organized transfer training based on quality courses from DXYuan, covering promotional, medical, and marketing personnel across all departments and hospitals. This training focused on seven core themes, including identifying and managing public opinion risks in medical and scientific information dissemination, ensuring marketing compliance in the AI era, the fundamental principles of building a doctor's personal brand (IP), and leveraging AI to lead a new era of promotion. The initiative comprehensively empowers the Group's new media operations and drives the standardized and efficient execution of related tasks.

Supply Chain Management

Chaoju Eye Care consistently adheres to the principle of "efficiency enhancement," continuously optimizing operational efficiency across all stages of the supply chain while ensuring medical quality. Simultaneously, we implement scientific procurement management to refine the overall cost structure, achieving effective savings and control over expenses.

The Group categorizes suppliers into material suppliers[1] and service suppliers, establishing the Supplier Management Measures. We strictly follow the principles of "strict qualification, quantitative evaluation, withdrawal for faults, and dynamic management" to implement standardized lifecycle management of suppliers, covering development, qualification, collaboration, evaluation, grading, assessment, and elimination. During the Reporting Period, we revised the Xiamen Chaoju Medical Technology Group Co., Ltd. Engineering Procurement Management System and established a dynamic assessment mechanism for suppliers covering dimensions such as construction management, quality, and progress, further solidifying the supplier reserve system.

During the supplier qualification and contract renewal phases, we verify the compliance of relevant supplier qualifications and review administrative penalty records through authoritative information platforms such as the National Medical Products Administration website, making this a prerequisite for collaboration. Throughout the cooperation period, the Group conducts annual evaluations of its suppliers based on the Supplier Evaluation Form. Guided by the principle of "survival of the fittest," suppliers are classified into five levels: "Strategic, Excellent, Good, Qualified, and Eliminated." Suppliers rated as unqualified and placed on the blacklist will have their cooperation qualifications revoked.

We prioritize selecting suppliers with a strong sense of social responsibility and issue the Integrity Self-Discipline Notification Letter to suppliers at the beginning of each year, urging them to adhere to business ethics. Simultaneously, we have established rigorous procedures to monitor and prevent any form of commercial bribery, ensuring transparency and integrity in all partnerships.

The Group also prioritizes suppliers with environmental qualifications to minimize environmental impacts. For example, when procuring office furniture, we explicitly require the use of E1-grade environmentally friendly materials and strictly limit emission indicators such as formaldehyde and volatile organic compounds. In hospital renovation projects, we mandate that design suppliers comply with environmental and safety-related standards from the design phase. Renovation materials must meet stringent criteria, including A-grade fire resistance levels, and during tendering, we require construction contractors to provide quotations based on high-quality and compliant materials, ensuring the overall project quality meets the stringent requirements of hospital-specific usage scenarios.

During the Reporting Period, the Group continued to advance its supply chain digitalization efforts. By integrating the Office Automation System (OA) with the Network Computing System (NC), we effectively mitigated the risk of unauthorized procurement and strengthened group-wide control. We also developed monthly data dashboard models for reagents, pharmaceuticals, and key medical consumables, providing multidimensional analysis to support management decisions and enhance inventory management efficiency and capital utilization. Additionally, we independently developed an "AI Program for Equipment Maintenance Q&A" to assist hospital equipment maintenance personnel in efficiently addressing equipment malfunctions. Furthermore, the Group deepened the implementation of its "Excellence Program," establishing a standardized, efficient, high-quality, and cost-effective development pathway for hospital supply chain management staff, comprehensively enhancing hospital operational capabilities and supply chain cost-efficiency.





1 Material suppliers include administrative materials, medical equipment, optical products, and pharmaceuticals.

Information Security and Patient Privacy Protection

Information Security Management

Chaoju Eye Care strictly complies with legal and regulatory requirements, including the *Regulations on the Security Protection of Computer Information Systems of the People's Republic of China*, the *Cybersecurity Law of the People's Republic of China*, the *Personal Information Protection Law of the People's Republic of China*, and the *Data Governance Standard of Medical Institutions*. The Group has formulated a series of information management systems, such as the *Information Security Management Measures*, the *Information System Network Security Management Measures*, the *Information System Access Control Management Measures*, the *Information System Access Control Management Process*, the *Information System Risk Assessment Management Measures*, and the *Information System Risk Assessment Management Process*, establishing a comprehensive information security management framework and continuously enhancing its information security management standards.

Information Security Management Framework

Level	Department	Responsibilities
Decision-making level	Board of Directors	• Responsible for the overall information security management of the company. • Reviewing and making decisions on major information security matters of the company. • Determining acceptable risks and risk levels, among other responsibilities.
Management level	Information System Management Committee	• Coordinating internal information security efforts within the company. • Promoting the implementation of information security initiatives across the company. • Organizing the establishment, implementation, maintenance, and improvement of the company's information security framework, and providing resources to relevant personnel.
Executive level	Information Technology Department	• Responsible for the establishment, implementation, and daily operation of the information security management system. • Drafting information security policies and defining information security management requirements. • Ensuring the implementation of information system policies across the company. • Responsible for internal monitoring, evaluation, and continuous improvement of the information security framework.
	All departments and subsidiaries	• Adhering to and implementing the requirements of the information security management system.

We have successfully deployed the Chaoju H+ Healthcare Management System in 13 hospitals. By integrating intelligent diagnosis and treatment systems covering pre-admission, in-hospital, and post-discharge stages, we have achieved full-process digital management of diagnosis and treatment, providing patients with a more efficient and convenient medical experience. Leveraging the clinical data infrastructure of the Hospital Information System (HIS), we have enabled automated extraction and real-time monitoring of supply chain data. Additionally, we have developed a medical quality data dashboard to help management intuitively grasp key quality indicators, further advancing the refined management of medical services.To comprehensively enhance the Group's information security protection capabilities, we have upgraded the Internet Data Center (IDC) firewall with a Web Application Firewall (WAF) module to effectively defend against web application layer attacks and improve the security of the OA system and other external websites. We have deployed a dedicated log server to centrally record and store operational and security logs from all business systems, enhancing the ability to trace and respond to cybersecurity incidents. Furthermore, we have upgraded the antivirus software on all Group office computers to ensure virus definitions and protection features are up to date, thereby strengthening the security protection of office endpoints.

In order to continuously strengthen the Group's information security framework, we have established a regular internal audit mechanism to proactively identify potential risks and ensure overall information security. During the Reporting Period, we conducted 2 internal audits covering the NC and HIS systems at the Group headquarters, all subsidiary hospitals, and the optometry company. The audits addressed multiple dimensions, including change management, logical access, IT operations, and data quality, with a focus on key areas such as system upgrade procedures, account permission settings, password policies, the status of former employees' accounts, server security configurations, and data backup strategies. These measures were taken to ensure the security of information systems and the quality of data comply with regulatory standards. For issues identified during the audits, the Group has formulated detailed corrective action plans, requiring responsible departments to implement them within specified timelines. We continuously monitor and verify the effectiveness of these corrective measures, creating a closed-loop management process to ensure all issues are fundamentally resolved. As of the date of this report, the Group's HIS system has obtained the Tier III Certification for the Classified Protection of Cybersecurity in China. Should any information security breach occur, the Group will strictly adhere to the *Overall Emergency Response Plan for Information Systems* to initiate the handling process. Emergency response follows the principles of graded response and timely escalation. Upon occurrence, the affected unit must immediately take local measures for response and control to prevent escalation. If local measures are insufficient to effectively eliminate the impact, the case must be promptly reported to relevant handling personnel and control managers in the Information Technology Department, and external service providers must be coordinated to initiate emergency support as needed. If the incident may cause personnel casualties, property damage, or other serious consequences, the affected unit must also simultaneously contact external agencies such as public security, firefighting, medical, and insurance institutions to ensure comprehensive and timely emergency response.

Privacy Protection for Patients

The Group places great emphasis on protecting patient privacy and strictly complies with the *Personal Information Protection Law of the People's Republic of China* and other relevant laws and regulations. We have established internal documents such as the *Patient Privacy Protection System* to regulate employee conduct and ensure the confidentiality of patient information.

In practice, hospitals under the Group have fully implemented a "one doctor, one patient" service model. Clear signage is posted outside consultation rooms, and a queue management system is utilized to guide patients in an orderly manner, ensuring privacy throughout the consultation process. Additionally, hospitals assign designated personnel for on-site guidance and management, reminding patients to wait outside consultation rooms, further optimizing the order and environment of the consultation process, making the diagnosis and treatment process more efficient, comfortable, and private. We strictly stipulate that patient privacy information may only be used for diagnosis and treatment purposes. Without the explicit authorisation of the patient, no disease-related or other private information may be disclosed to others or used for teaching or training activities. Furthermore, stringent management is enforced regarding the storage and borrowing of both physical and electronic medical records, preventing arbitrary access by any individual.

During the Reporting Period, **no incidents** involving violations of patient privacy or loss of patient data occurred within the Group.

04 |

Prioritising Employees and Cultivating a Harmonious Workplace

- Employee Employment
- Employee Training
- Employee Rights and Benefits
- Employee Incentives and Promotion
- Employee Communication
- Occupational Health and Work Safety



Prioritising Employees and Cultivating a Harmonious Workplace

The Group strictly adheres to laws and regulations, including the *Labor Law of the People's Republic of China*, the *Labor Contract Law of the People's Republic of China*, the *Law of the People's Republic of China on the Protection of Minors*, and the *Provisions on the Prohibition of Using Child Labor*. We have established the *Management System for Assessment and Employment of Personnel at All Levels* and revised the *Chaoju Eye Care Technology Group Limited Employee Handbook* to standardize and safeguard the legitimate rights and interests of employees in areas such as recruitment, attendance, leave, communication, appeals, benefits, and care.

Employee Employment

The Group conducts recruitment through open and compliant channels, including online platforms and headhunter referrals. During the recruitment process, we truthfully inform candidates about key information such as job responsibilities, working conditions, workplace location, occupational hazards, and compensation. For the termination of employment relationships, we have established a standardized management mechanism to ensure all procedures are handled in accordance with laws and regulations. Employees have the right to refuse unreasonable demands and may request the company to make adjustments based on legal provisions.

The Group opposes and prohibits the use of child labour or any form of forced labour. We have implemented the Policy on *Prohibition of Child Labor and Procedures for Remedial Measures*, strictly verifying the identity of all applicants during recruitment. Should child labour be employed inadvertently, the Group will immediately cease their work, report the matter to the local labour bureau, and contact their legal guardian to ensure proper care. Re-employment may only be considered after the individual reaches the minimum legal working age. We explicitly prohibit forced labour by means of violence, threats, illegal restrictions on personal freedom, or any other similar means.

The Group is committed to fostering a diverse and inclusive work environment and strictly prohibits any form of discrimination based on gender, age, region, educational background, religious belief, nationality, ethnicity, sexual orientation, or disability.

During the Reporting Period, no incidents related to violations of labour standards—such as employee recruitment and dismissal, working hours and holidays, equal opportunity, diversity, or anti-discrimination—occurred within the Group.



Employee Rights and Benefits

The Group strictly implements national regulations and has established internal systems, including the *Employee Attendance and Holiday Management Measures* and the *Chaoju Eye Care Technology Group Limited Employee Handbook*, to protect the legitimate rights and interests of employees.

We adhere to the standard working hour system. For hospitals or optometry subsidiaries where job characteristics necessitate flexible working hours, we complete the filing application with the labour authorities in accordance with regulations. If overtime is required due to unexpected or temporary work tasks, approval must be obtained from director-level or higher management, with compensation provided through compensatory time off or overtime pay.

Regarding leave entitlements, the Group ensures that employees are lawfully entitled to national statutory holidays, as well as personal leave, sick leave, marriage leave, bereavement leave, maternity leave, breastfeeding leave, paternity leave, paid annual leave, and home visit leave, thereby safeguarding employees' rights to rest and vacation.

Furthermore, the Group provides employees with diverse benefits, including staff dormitories, meal allowances, transportation allowances, and communication subsidies. We also conduct care and support activities for employees who are ill or on maternity leave, and organize themed team-building events such as birthday celebrations and sports activities, fostering a warm corporate atmosphere and enhancing employee cohesion and sense of belonging. Simultaneously, the Group places great importance on the well-being of female employees, granting all female staff a half-day holiday on International Women's Day and distributing festive gifts.

Case International Women's Day Female Care Activities

Chaoju Eye Care actively implements ESG principles and continuously focuses on the growth and development of female employees, earnestly fulfilling its commitment to gender equality and employee care. During International Women's Day, we specially prepared holiday gifts for all female colleagues to express our gratitude for their hard work. This initiative not only serves as sincere recognition of their professional contributions but also embodies the company's best wishes, inspiring everyone to continue pursuing light in the ophthalmology field and to use their professionalism and love to light up a bright future for more patients.



Employee Communication

The Group has established a comprehensive employee communication and feedback mechanism, emphasizing and actively listening to employee voices. Employees can provide feedback and suggestions through designated channels such as email and internal grievance procedures. Additionally, the Group conducts annual employee surveys to systematically gather opinions and concerns from employees regarding compensation and benefits, career development, working environment, and other matters. This enables timely understanding of grassroots needs and provides a critical basis for management decisions and continuous improvement.

Employee Training

During the Reporting Period, Chaoju Eye Care, aligned with the Group's strategic development objectives and sustainability requirements and guided by the core philosophy of "Empowering the Foundation, Fostering Growth," established a comprehensive, multi-level, and full-cycle talent development system covering new employees, existing staff, management personnel, and specialized technical talents. We formulated core policies, including the *Management Measures for Enhanced Surgical Training*, the *Internal Trainer Management Measures*, and the *Management Measures for Employee External Training*, enabling full-process management of pre-training planning, in-process monitoring, and post-training evaluation. The Group also revised enhanced surgical training plans and corresponding assessment forms for four categories, such as phacoemulsification and intraocular lens implantation, thereby improving the compliance and specificity of training initiatives. At the same time, by establishing two core management ledgers—*Signing of Employee Training Special Agreements* and *OA Process for Enhanced Surgical Training*—the Group has achieved full lifecycle traceability and control over key stages such as project initiation, cost management, and service duration for training programs, effectively enhancing the standardization of training operations management.

The Group has completed the construction of Phase 1.0 of the Chaoju Eye Care Training Curriculum System, having developed a total of 108 courses across four core curriculum clusters: the Basic Series, the On-the-Job Personnel Series, the Management Personnel Series, and the Internal Trainer Series. The course reuse rate reached 65%, enabling efficient circulation and maximization of value from high-quality content. Currently, the "Exam Star" learning platform has created over 150 learning projects, with online training penetration increasing to 55%. Employees have accumulated more than 36,000 hours of online learning, and the course completion rate stands at 91%, reflecting the deep integration of digital learning into daily operations. We have established a trinity faculty team comprising "external experts, internal senior executives, and internal part-time trainers," inviting industry association experts, renowned hospital specialists, and external consultants to participate in course instruction. Simultaneously, we continue to deepen the development of our internal trainer team, creating instructor profiles and establishing an internal course library with over 120 modules. Currently, internal course coverage has increased to 70%, and the Group's capacity for self-supply of internal training resources continues to strengthen.

To facilitate the deep integration of training with business development, we focus on four core dimensions: system optimization, project innovation, resource integration, and operational upgrades. Throughout the year, over 50 training programs were implemented, covering more than 2,300 participations, with a 100% coverage rate for core positions, providing robust talent support for the high-quality sustainable development of the Group's ophthalmic healthcare services. The Group has achieved standardized and regulated management of all training materials, including courseware, lesson plans, and evaluation forms. This has resulted in a well-structured and easily accessible training resource library, laying a solid foundation for future training initiatives.

The Group has developed a total of **108** courses

The course reuse rate reached **65%**

creating instructor profiles and establishing an internal course library with over **120** modules

Currently, internal course coverage has increased to **70%**

Throughout the Reporting Period, over **50** training programs were implemented with a **100%** coverage rate for core positions

New Employee Training

The Group cumulatively trained **420** new employees

achieving a program completion rate of **98.5%**

The efficiency of new employees adapting to their roles within the first three months of employment increased by **30%**

The Group continues to deepen the development of its new employee training system. The new employee training program currently covers multiple hospitals across the headquarters and regions such as Inner Mongolia, Chifeng, Beijing, and Zhejiang, operating throughout the year with ongoing content and process optimization. We have established a closed-loop management system encompassing "learning platform – task flow – signature confirmation – comprehensive assessment – certification," ensuring standardization, traceability, and measurability in new employee training, thereby facilitating their smooth integration into the workplace. Regarding training assessments, the Group has introduced additional evaluation components related to hospital operations, clarifying behavioral standards for employees and effectively mitigating employment-related risks.

During the Reporting Period, the Group cumulatively trained 420 new employees, achieving a program completion rate of 98.5%. Through systematic training, the efficiency of new employees adapting to their roles within the first three months of employment increased by 30%, providing a standardized and replicable model for talent pipeline development in hospitals across various regions.

On-the-Job Employee Training

The Group conducted a total of **31** specialized training sessions

The average satisfaction rate for these sessions reached **96.2%**

driving a **28%** increase in satisfaction for related business services

During the Reporting Period, the Group conducted a total of 31 specialized training sessions for all headquarters staff and selected hospital personnel, covering topics such as AI Technology Boosting Office Efficiency and Practical Applications of Enterprise WeChat Scenarios, among other digitalization-focused courses. The average satisfaction rate for these sessions reached 96.2%. We prioritized the development of an AI question bank, completing the construction of a corporate-level examination question library system. This system fully supports the customized examination management needs of the Group and its subsidiaries, enabling intelligent allocation and sharing of training resources.

Currently, training and capability building are extending deeply toward the business front. Taking the specialized training for intraocular injections as an example, eight hospitals have proactively studied and adopted the fundus injection operation model of Jiaxing Hospital after the training, driving a 28% increase in satisfaction for related business services. This has formed a positive cycle of "training input – model replication – business improvement," clearly demonstrating the direct value of training programs in driving business growth.

Management Personnel Training

Covering approximately **400** mid-level employees from various hospitals

Post-training assessments indicate an approximate **40%** improvement in team execution performance scores

The Group conducts a variety of training programs for management personnel to comprehensively enhance managerial effectiveness and strategic execution capabilities. We continue to operate the "Dean Training Camp (Executives on Growth)" series, inviting industry experts and Group executives to deliver lectures on topics such as the promotion of the Sanming model and myopia prevention and control, disseminating management wisdom and industry experience. Furthermore, we have launched the "Hospital Backbone Management Capability Enhancement Camp" and mid-level cadre capability improvement projects in Bayannur League/Zhejiang regions, covering approximately 400 mid-level employees from various hospitals. Post-training assessments indicate an approximate 40% improvement in team execution performance scores.

Case **"Navigating Excellence Plan: Honing Management Core" – Chaoju Eye Care's Special Training Camp on "Project Management Practice" for Middle and Senior Executives.**

In September 2025, Chaoju Eye Care successfully held the "Navigating Excellence Plan: Honing Management Core" – Special Training Camp on "Project Management Practice" for Middle and Senior Executives. Ninety-six core management personnel participated, aiming to comprehensively enhance the practical project management capabilities of middle and senior managers, thereby providing robust support for the effective implementation of the "Excellence Plan".

This training specially invited a renowned project management expert in the industry as the lead instructor. The curriculum focused on key modules such as "Strategic Alignment, Resource Synergy, Value Identification, Efficient Execution, Project Monitoring, Risk Resolution, and Critical Breakthroughs". Through diverse formats including thematic lectures, case studies, and practical simulations, the training comprehensively enhanced participants' project management mindset and practical skills. The course content was closely integrated with the characteristics of the healthcare industry, emphasizing the deep integration of theory and practice. It systematically equipped participants with comprehensive management methodologies covering the entire process from project initiation to acceptance and review.



Cultivation of Professional and Technical Talents

We will continue to promote the postgraduate study program, synchronize it with the resident physician curriculum system, and integrate the Standardized Training for Ophthalmic Resident Physicians and the Chaoju & Wenzhou Medical University Bright Guardianship Course Series to achieve deep integration between postgraduate education and clinical practical training. The "Spark Plan – Resident Physician Transformation Journey" will be implemented, offering a 24-class-hour specialized course on fundus knowledge. This course invites a team of ophthalmology experts from Peking University Third Hospital and internal Group experts to deliver joint instruction, covering more than 150 resident physicians and postgraduates. After the training, the standardized compliance rate for clinical operations increased by 45%. Additionally, projects such as the "Basic Standardization Course for Cataract Phacoemulsification" and the "Standardized Training for Fundus Laser and Fluorescein Angiography" have been conducted. Through formats including "offline intensive training, animal eye practice, online theoretical instruction, and offline regional practice," a total of 117 professional and technical talents have been cultivated, with a skill assessment pass rate of 92%.

Offering a
24-class-hour specialized course on fundus knowledge

covering more than
150 resident physicians and postgraduates

After the training, the standardized compliance rate for clinical operations increased by
45%

The specialized training for intraocular injections achieved a comprehensive score of
99.83

During the year, the Company regularly conducted employee training satisfaction surveys and continuously iterated and optimized training quality based on employee feedback. Among these, the specialized training for intraocular injections achieved a comprehensive score of 99.83. We have enhanced the training management system from two key dimensions: process standardization and assessment evaluation:

Management system

Standardization of Training Processes
- We have optimized the end-to-end management of training, covering application, review, implementation, evaluation, and archiving. By leveraging the OA system, we have established online control for enhanced surgical training workflows, ensuring efficient coordination and standardized execution across all stages.

Training Assessment and Evaluation
- A diversified assessment and evaluation system comprising "Attendance + Topic Sharing + In-class Testing + Effectiveness Evaluation" has been established. This system has been expanded to include hospital-specific professional examinations and assessments of employee behavioral standards.

Employee Incentives and Promotion

The Group has formulated the Employee Compensation Management Measures. Employee salaries consist of basic pay, position-based pay, and performance-based pay, which are set competitively with differentiation based on rank and experience. Social insurance contributions are made in full and in accordance with the law. Furthermore, we grant equity to the management team, core doctors, and long-serving employees, enabling them to share in the rewards of their dedication and fostering medium- to long-term incentives. The Group strictly enforces a salary confidentiality policy; unauthorized access to another employee's salary information will be treated as a serious violation of company regulations.

The Group has established a performance-centric talent development and incentive system. Policies including the *Employee Performance Management Measures* and the *Management Measures for Performance Awards of Subsidiary Business Teams* have been formulated to create a performance management framework, assessment standards, and incentive policies for key positions, ensuring employees' outstanding contributions are fully recognized. Based on performance evaluation results and market benchmarks, salary adjustments are made for high-performing employees, while coaching and empowerment are provided for those requiring performance improvement. This approach drives the achievement of performance goals while promoting the continuous enhancement of employees' capabilities, thereby achieving mutual promotion between organizational objectives and individual development.

The Group has formulated management systems including the *Management Measures for Reserve Cadre Cultivation*, the *Employment Management Measures for Middle-level Management Personnel of Subsidiaries*, and the *Employee Career Development and Promotion Management System*, providing standardized guidelines for employees' career development. We have established three distinct career development paths for employees—management, professional expertise, and job rotation—to broaden their career progression opportunities. At the selection level, we adhere to a combined approach of subsidiary recommendation and Group selection. Employees are selected for targeted development based on their organizational and management capabilities, as evidenced by their performance evaluation results, daily conduct, and developmental potential. This ensures that the direction of personal growth is closely aligned with the Group's strategic objectives, fostering synergy between talent development and organizational advancement.

Occupational Health and Work Safety

The Group has established a comprehensive management structure for occupational health and work safety, with independent management of its subsidiary hospitals. Taking Hohhot No.2 Hospital as an example, the hospital has set up a Work Safety Management Committee, with the hospital director serving as the chairperson and responsible for formulating the hospital's safety control plan and labour protection measures. The committee comprises members and safety officers who are specifically tasked with implementing safety inspections and supervision, conducting oversight and effectiveness assessments of medical safety controls, ensuring the comprehensive implementation of the work safety management system.

Occupational Health Management

To standardize occupational health management, we have established the *Occupational Health Management System* and the *Occupational Safety Protection and Health Examination System*. We regularly commission qualified third-party organizations to monitor and assess occupational disease hazard factors in the workplace. This process identifies primary occupational disease risk positions, including radiology staff, healthcare personnel, and medical waste disposal workers, and pinpoints hazard factors such as ionizing radiation, infectious waste, and sharp instrument injuries. For positions with occupational health hazards, we conduct risk notifications to employees before they commence work. Employees exposed to occupational hazard factors are provided with personal protective equipment such as lead aprons, lead collars, masks, and gloves, and their proper use is supervised. Furthermore, the Group consistently maintains, services, and upgrades occupational disease protection facilities to ensure their effective operation. Regular occupational health examinations are also organized, and occupational health records are established for relevant personnel to enable ongoing tracking and management of their health status.

The Group has developed specific emergency response plans for occupational disease hazards. Taking needle-stick injuries among medical staff as an example, the plan standardizes procedures including immediate wound treatment, timely reporting, preventive medical intervention, and comprehensive record-keeping to systematically address occupational exposure risks.

We consistently conduct specialized training covering occupational exposure prevention and response, medical waste disposal and safety protection, hand hygiene, and infectious disease prevention and control. This training helps employees systematically master relevant protective knowledge and practical skills, thereby strengthening overall safety capabilities and reducing occupational risks.

The Group has formulated policies including the *Reporting and Management System for Occupational Exposure*, the *Occupational Exposure Protection System*, and the *Post-Sharp Injury Treatment Plan*. All subsidiary hospitals are required to establish an Infection Management Department, staffed with qualified personnel as per regulations, to systematically standardize the prevention, reporting, and handling procedures for occupational exposure. In daily operations, we strictly enforce all safety protocols and provide employees with necessary personal protective equipment. Furthermore, the Group has established comprehensive emergency response procedures for occupational exposure to ensure swift and effective handling of incidents, fully safeguarding the health and safety of our staff.

Emergency Treatment Procedures for Occupational Exposure


Emergency treatment	Inspection and reporting	Regular follow-up
• In the event of occupational exposure, immediately wash the affected skin area with soap and running water, and rinse mucous membranes repeatedly with saline to treat the wound.	• The Infection Control Department guides exposed individuals to receive antiviral drugs for prophylactic treatment and conducts regular blood tests. • Report incidents promptly, investigate the exposure source and severity, and guide the relevant department's medical staff to adopt necessary preventive measures	• Monitor and record the physical condition of the exposed individual. • Schedule follow-up examinations based on the nature of the disease involved.

Work Safety Management

The Group strictly adheres to laws and regulations including the *Work Safety Law of the People's Republic of China*. With the goal of achieving "zero accidents, zero injuries", we have established systems such as the *Compilation of Work Safety Systems* and the *Accident Risks Investigation and Governance System* to effectively ensure production safety.

- Practical safety training materials are developed based on the actual job content of different positions. Regular thematic training sessions on fire safety, public safety, and occupational health are conducted, alongside relevant emergency drills, to continuously enhance employees' safety awareness and practical skills.

- Following the *Safety Risk Grading Control Work System*, we systematically identify and analyze various hazards in production and business operations, assess their risk levels, and implement graded control measures.



- In accordance with the *Accident Risks Investigation and Governance System*, regular hazard inspections are carried out. Identified risks must be rectified within a specified timeframe, with follow-up review and performance assessment mechanisms in place to ensure thorough resolution.

- Specific emergency response plans are developed for critical areas such as security, fire safety, elevators, and pressure steam sterilizers. Regular training and practical drills are conducted for relevant personnel.

During the Reporting Period, the Group did not receive any penalties for violating work safety or occupational health laws and regulations, and recorded

0 work-related fatalities.

05 |

Cherishing the Environment and Fostering Green Development

- Resource Management
- Climate Change Response
- Emissions Management





Cherishing the Environment and Fostering Green Development

Resource Management

Energy Management

The Group strictly complies with laws and regulations including the *Energy Conservation Law of the People's Republic of China* and the *Electric Power Law of the People's Republic of China*. We have formulated the *Energy Management System*, the *Water and Electricity Management System*, and the *Hospital Energy Conservation and Consumption Reduction Management System* to standardize energy management across the Group and its subsidiary hospitals. Goals for energy conservation have been set to promote the implementation of energy-saving and emission-reduction measures, thereby better fulfilling our environmental protection responsibilities. We carry out energy conservation awareness campaigns and training to encourage employees to develop energy-saving habits, foster a culture of conservation within hospitals, and promote the normalization of energy-saving and emission-reduction efforts.

Electricity saving measures

Responsibility Management

- Establish a departmental electricity quota system, clarify requirements for switching off equipment and lighting during non-clinical hours; designate electricity management responsibility zones by area, appointing department heads as energy conservation responsible persons, implementing a "lights off when leaving, power off when idle" accountability mechanism; install smart meters to monitor electricity consumption in real time, conducting targeted control over high-consumption departments; administrative duty personnel conduct daily inspections to promptly turn off lighting in public areas that was not switched off in time.

Equipment Energy Efficiency Management

- When adding or replacing equipment such as air conditioners, medical refrigerators, and electromechanical devices, prioritize purchasing products with Tier 1 energy efficiency ratings and phase out high-energy-consumption equipment; optimize equipment operating schedules, scheduling non-urgent clinical procedures to avoid peak electricity tariff periods; configure computers and printers with automatic sleep modes to reduce standby energy consumption.

Lighting System Upgrades

- Replace lighting in public and non-renovated areas with energy-efficient LED fixtures, utilizing sound-activated, light-sensitive, or motion-sensor switches; install smart meters in consultation rooms and offices for real-time monitoring of electricity usage.

Air Conditioning and Temperature Control Management

- Set air conditioners to energy-saving mode, maintaining cooling temperatures no lower than 26°C in summer and heating temperatures no higher than 20°C in winter; reasonably adjust air conditioning operating schedules, switching them off in advance before end-of-day; apply window films and install sealing strips to minimize cooling or heating loss; regularly monitor temperature and humidity in storage and clinical areas to prevent energy waste.

Fuel saving measures

Process Optimization

- Refine the *Vehicle Management System* to allocate vehicles based on operational need and reduce dispatch frequency; require advance notification and approval of trips, plan routes efficiently to minimize non-essential ad hoc usage; conduct regular spot checks and issue reports to prevent unauthorized vehicle use.

Vehicle Dispatch

- Departments must submit vehicle requests in advance; assignments are made based on trip routes to avoid repeated dispatches; priority is given to the procurement of new-energy vehicles.

Vehicle Maintenance

- Conduct regular vehicle inspections and maintenance to ensure optimal performance, reducing fuel leaks or excessive consumption; install diesel-powered heaters to decrease fuel consumption during vehicle startup and idle warm-up time in low-temperature winter conditions.

Gas saving measures

- During the winter heating period, heating schedules and temperatures are reasonably set according to weather changes and patient needs to avoid unnecessary natural gas consumption.

This year, Chaoju (Inner Mongolia) Eye Hospital and Chaoju (Sihong) Eye Hospital have established quantified energy usage targets.

	Goals for 2025	Progress on 2025 Goals	Goals for 2026
Chaoju (Inner Mongolia) Eye Hospital	Achieve a **10%** reduction in direct energy consumption compared to the 2024 baseline.	In 2025, direct energy consumption decreased by **15%** compared to 2024.	Achieve a **5%** reduction in direct energy consumption compared to the 2025 baseline.
Chaoju (Sihong) Eye Hospital	Achieve a **5%** reduction in direct energy consumption compared to the 2024 baseline.	In 2025, direct energy consumption decreased by **8%** compared to 2024.	Achieve a **10%** reduction in direct energy consumption compared to the 2025 baseline.

Water Resource Management

The Group strictly complies with the *Water Law of the People's Republic of China*, and has formulated the *Water Resource Management System* to strengthen water resource management and promote the conservation of water resources. The Company has also set a directional target for water use efficiency, namely: In accordance with the Group's water conservation measures, actively implement their execution and maintain or gradually reduce water consumption intensity under similar conditions of business operations. This year's target has been achieved, and there is no issue in sourcing water that is fit for purpose.

Water saving measures

Water-Saving Equipment Upgrades

- Uniformly use water-saving lever-handle faucets or sensor-activated faucets (except in departments with special requirements); install water-saving aerators to reduce flow and prevent splashing; adopt graded water-use modes in operating rooms, dental departments, etc., to avoid direct discharge of clean water and reduce waste.

Inspection and Maintenance Mechanism

- Designate water-use responsibility zones by department, with assigned personnel responsible for daily inspections; regularly check water-using equipment and promptly address leaks in pipes, valves, and faucets; establish a rapid-response leak-repair reporting mechanism to ensure immediate repair upon detection of issues.

Water Resource Recycling

- Reuse unused boiled water from office kettles the following day for cleaning purposes.

Water-Saving Awareness Cultivation

- Display water-conservation signage in office and operational areas to reinforce employees' awareness of water resource conservation.

Emissions Management

The Group strictly complies with laws and regulations such as the *Atmospheric Pollution Prevention and Control Law of the People's Republic of China*, the *Water Pollution Prevention and Control Law of the People's Republic of China*, and the *Law of the People's Republic of China on the Prevention and Control of Environmental Pollution by Solid Waste*. We have formulated systems including the *Medical Wastewater Management System* and *Medical Waste Management System*, and strictly control emissions generated from our principal business activities in accordance with national and industry discharge standards. Regular monitoring of emissions such as exhaust gases and wastewater is conducted to ensure that all emissions are treated compliantly and discharged up to standard, thereby preventing pollution of the atmosphere, water bodies, and soil. During the Reporting Period, the Group complied with relevant laws and regulations that have a significant impact on the Group, and there were no incidents of pollutant emissions exceeding standards or violating regulations, nor any lawsuits arising from such matters.

The Group has established targets for compliant waste disposal:

Goals for 2025	Progress on 2025 Goals	Goals for 2026
100% of the Group's hazardous waste is entrusted to qualified third-party processors for disposal.	Achieved	100% of the Group's hazardous waste is entrusted to qualified third-party processors for disposal.

Types of Emissions and Management Measures

Type	Monitoring indicators	Management standards	Management measures
Wastewater	Medical and domestic wastewater; and the monitoring indicators include COD, BOD, and ammonia nitrogen (NH_3- N).	*Discharge Standard of Water Pollutants for Medical Organisations* (GB18466-2005)	Install filtration devices on processing equipment to intercept particulate matter and prevent it from entering medical wastewater drainage channels; adopt A/O + disinfection processes for pre-treatment of wastewater, with sewage discharged into the municipal sewage network after pre-treatment. All hospitals under the Group monitor bacterial species and physicochemical indicators in wastewater as required. Monitoring results indicate that wastewater discharges from the Group's hospitals are within standard limits and comply with discharge standards.
Exhaust gas	Odour generated During wastewater treatment, mainly hydrogen sulphide (H_2S) and ammonia (NH_3)	*Discharge Standard of Water Pollutants for Medical Organisations* (GB18466-2005) – Maximum allowable concentrations of air pollutants around wastewater treatment facilities.	Gas collection systems are installed in wastewater treatment rooms. Collected exhaust gases undergo purification through activated carbon adsorption units, and the treated gases are discharged via rooftop ducts. Additionally, exhaust fans are added in processing workshops to enhance ventilation effectiveness.
Non-hazardous waste	Domestic waste and packaging of disposable consumables	*Standards for Pollution Control on the Non-hazardous Industrial Solid Waste Storage and Landfill* (GB18599-2020)	Centralised collection of nonhazardous waste, with categorisation before disposal into recyclable waste, non-recyclable waste, kitchen waste, and other waste. Recyclables are reused where possible.
Hazardous waste	Medical waste, Mainly infectious and injurious waste, including medical and chemical waste, used ink cartridges, toner cartridges, batteries, and scrapped IT equipment	*Standard for Pollution Control on Hazardous Waste Storage* (GB18597-2001)、*Regulations on the Administration of Medical Waste*、*Technical Specifications on Centralised Disposal of Medical Waste (Trial)*	Classification, packaging, sealing, and temporary storage of hazardous waste in accordance with regulatory labelling. Medical hazardous waste is uniformly and safely disposed of by authorised third-party contractors.

Climate Change Response

Governance

We have fully integrated climate change response into the Group's ESG governance structure. The Board of Directors of Chaoju Eye Care serves as the highest supervisory and governance body for climate change matters, bearing ultimate responsibility for the Group's climate-related strategies and reporting. The Board's Environmental, Social and Governance Committee oversees and provides recommendations on the overall climate change response strategy, the identification, assessment and management of climate risks and opportunities, as well as climate-related targets and major response measures. It ensures that climate factors are incorporated into material decision-making, and reports annually to the Board on relevant assessment results, strategic progress, and target achievement. The ESG management system, coordinated by various departments and subordinate units of the Group, assumes daily governance and coordination responsibilities for climate risks and opportunities. It specifically implements climate response strategies approved by the Board, cooperates in climate risk and opportunity response and supervision according to respective business responsibilities, and incorporates relevant work into routine risk management.

Members of the Board possess diverse professional backgrounds, including expertise in corporate management, medicine, finance, law, and industry, enabling them to effectively understand and oversee climate-related risks and opportunities. The Group regularly invites third parties to conduct climate-related thematic training or sharing sessions for the Board and management, helping them understand the latest changes in climate change guidance and response measures, and enhancing their professional understanding and competency in climate-related matters.

Strategy

Chaoju Eye Care responds to China's national strategy of peaking carbon emissions by 2030 and achieving carbon neutrality by 2060, fully recognizing the potential impacts of climate change on the Company's operations, financial performance, and long-term sustainable development. The Group actively carries out the identification and assessment of climate-related risks and opportunities, formulates corresponding response strategies, reduces potential adverse impacts from climate-related risks, and actively seizes climate-related opportunities.

Based on reasonably expected policy environments, economic conditions, natural factors, and technological conditions, the Group comprehensively considers major uncertainties in the natural environment, policy, market, and technology based on actual conditions. With reference to the Shared Socioeconomic Pathways (SSP) scenarios in the Intergovernmental Panel on Climate Change Sixth Assessment Report (IPCC AR6) aligned with international climate change agreements, and the Green Finance Network (NGFS) scenarios, and assessing industry applicability, the Group supplements with the "Net Zero 2050" and "Current Policies" scenarios published by the Network for Greening the Financial System (NGFS) to assess the adaptability of the Group's strategy, business model, and all operating locations to climate physical risks and transition risks in the short, medium, and long term.



Major Climate-Related Risks and Response Strategies

Risk Type and Description			Exposure Under Different Scenario Assumptions				Response Strategy	Current and Expected Financial Impact
			High Emission Scenario Portfolio		Low Emission Scenario Portfolio			
			2030	2050	2030	2050		
Physical Risk	Acute Risk (Short-term[2])	**Business operations** The increasing frequency of extreme weather events such as heavy rain, typhoons, and sandstorms may lead to power outages and flooding at the Group's hospitals or optical centers, resulting in temporary suspension of hospital operations and inconvenience for employee commuting.	Low	Low	Low	Low	Before the onset of extreme weather events such as heavy rain, typhoons, and sandstorms, the Group issues timely notifications to ensure employee safety and establishes emergency response mechanisms to enhance emergency handling capabilities.	**Current Financial Impact:** Based on assessment, no impact on the Company's financial position, financial performance, and cash flows. **Expected Financial Impact:** If extreme weather disasters occur frequently, the Company's relevant prevention drills, equipment and facility investment, and asset losses may continue to increase, and related insurance costs will rise.
	Chronic Risk (Short-term, Medium-term)	**Business operations** Continued rise in average temperatures, with significantly increased usage and electricity consumption of cooling equipment during high-temperature weather. Continued rise in average temperatures, with significantly increased usage and electricity consumption of cooling equipment during high-temperature weather.	Low	Low	Low	Low	Formulate tiered temperature control standards to avoid excessive cooling; Gradually replace outdated air conditioners with high-efficiency equipment.	**Current Financial Impact:** Based on assessment, no impact on the Company's financial position, financial performance, and cash flows. **Expected Financial Impact:** Future early retirement of outdated equipment to improve energy efficiency may result in one-time replacement costs.
Transition Risk	Policy and Legal (Long-term)	**Business operations** As the Chinese government advances its "dual carbon" goals, the healthcare industry faces stricter emission standards and energy efficiency requirements.	Low	Low	Low	Low	Continue advancing energy conservation and emission reduction measures such as LED lighting upgrades and phasing out high-energy-consumption equipment; Prioritize procurement of medical devices and consumables with green certifications; Establish emission reduction targets and specific action roadmaps, and enhance credibility through third-party certification.	**Current Financial Impact:** Based on assessment, no impact on the Company's financial position, financial performance, and cash flows. **Expected Financial Impact:** If the Company fails to comply with future emission requirements, compliance costs such as carbon taxes and fines for exceeding standards may need to be paid.

Major Climate-Related Opportunities and Response Strategies

Opportunity Type and Description		Exposure Under Different Scenario Assumptions				Response Strategy	Current and Expected Financial Impact
		High Emission Scenario Portfolio		Low Emission Scenario Portfolio			
		2030	2050	2030	2050		
Products and Services (Medium-term, Long-term)	**Business operations** Promoting telemedicine and electronic medical records can provide services to patients when they are unable to travel due to climate factors such as extreme weather.	Low	Low	Low	Medium	The digital diagnostic and treatment auxiliary intelligent agent "Doctor Zhang Mulan" launched by the Group can complete the full-process assistance from doctor-patient consultation dialogue to generating outpatient medical records, preliminary diagnosis, and providing treatment plans.	**Current Financial Impact:** As an auxiliary tool, intelligent agents make it difficult to draw a clear and quantifiable distinction from daily revenue. We are unable to independently identify their current and expected financial impacts. **Expected Financial Impact:** In the future, the Group will focus on two core directions: medical intelligent agents and management intelligent agents, reconstructing ophthalmic diagnosis and treatment models and management systems through AI technology, which will help continuously increase the Company's revenue.

2 Based on a comprehensive consideration of the Group's core business planning and external reference information, we have set the time horizons for climate-related risk impacts as follows: short-term (within 1 year after the end of the Reporting Period), medium-term (1 to 5 years after the end of the Reporting Period), and long-term (more than 5 years after the end of the Reporting Period).

The analysis results indicate that during the Reporting Period, the aforementioned climate-related risks did not have a significant impact on the Group's financial position, financial performance, and cash flow, and are not expected to have a significant impact on the carrying amounts of assets and liabilities in the next reporting period. Through actively expanding the application of intelligent assistants and strengthening risk management, the Group is able to effectively respond to challenges under different climate scenarios and seize relevant opportunities. We will continue to monitor the relevant risk conditions and prudently assess their potential impact on the Group's long-term financial resilience.

Part of the content mentioned above includes forward-looking statements, which do not constitute guarantees, forecasts, or predictions of future circumstances. In this process, the Company has considered numerous uncertain factors, including economic, regulatory, market, geopolitical, and climate pattern factors. These uncertain factors are subject to limitations in data sources and assessment methodologies, and may also be influenced by other unobserved uncertain factors and subjective judgments. Going forward, the Company will continue to monitor relevant risks and opportunities, and update scenario analysis results after significant changes occur in business models or scenario assumptions. Furthermore, based on the above uncertainties, and after comprehensively considering the feasibility of separately identifying expected financial impacts, the feasibility of consolidating other climate-related risks and opportunities for comprehensive financial impact disclosure, as well as the Company's current capabilities and resources, the Company has decided to temporarily adopt a qualitative approach to disclose the expected financial impacts of sustainability risks and opportunities, including climate change.

Risk Management

Chaoju Eye Care has integrated climate change-related risks into the Group's overall risk management system. Based on actual business conditions, combined with scenario analysis results, industry analysis, and external expert advice, we regularly identify and analyze potential risks and opportunities brought by climate change. Through the identification and analysis mechanism, we systematically strengthen climate risk management capabilities. For identified climate-related risks and opportunities, the Group comprehensively considers their likelihood of occurrence and impact on finances and operations based on departmental feedback, prioritizes risks and opportunities, and develops targeted response measures. Going forward, the Group will continue to track, monitor, and dynamically assess the effectiveness of climate risk and opportunity management.

Please refer to the "Risk Management and Internal Control" and "Materiality Topic Identification" sections of this report for details.

Metrics and Targets

During the year, the Group advanced the accounting of Scope 3 greenhouse gas (GHG) emissions in an orderly manner based on the internationally recognized Greenhouse Gas Protocol: Corporate Value Chain (Scope 3) Accounting and Reporting Standard (2011), continuously improving its GHG emissions accounting and management system. For Chaoju Eye Care's key GHG emissions performance indicators in 2025, please refer to the Appendix.

Based on the identification and assessment of climate-related risks and opportunities, the Company focuses on analyzing their potential impact on assets and business activities to clarify priorities for climate management. Overall, the Company's hospitals and equipment assets are more susceptible to climate physical risks, with a value of RMB 578.599 million, accounting for 19% of total assets. The Company's climate-related opportunities mainly relate to research and development investments in intelligent agents; due to commercially sensitive information, relevant quantitative data is not yet provided. During the year, the Company had no capital expenditure, financing, or investment amounts allocated to climate-related risks and opportunities.

Based on the Group's actual conditions and prudent analysis of future scenarios, the impact of climate change on Chaoju Eye Care is not significant. However, the Group remains committed to actively assuming environmental responsibilities and contributing to climate change response and mitigation. The Company has established specific energy use targets and will further plan greenhouse gas emission reduction targets to promote systematic sustainable development practices.

06 |

Passing Love and Engaging in Charitable Actions

- Volunteer medical consultation and vision screening
- Eye health knowledge dissemination
- Enhancing ophthalmic diagnosis and treatment capacity development



Passing Love and Engaging in Charitable Actions

This year, the *Group issued the Standardised Management System for Social Public Welfare (Trial Version)*, leveraging its resources and expertise in ophthalmology to provide community residents with services such as volunteer medical consultations, screenings, and health education, thereby continuously safeguarding public eye health.

Volunteer Medical Consultation and Vision Screening

We actively fulfill our social responsibilities and are deeply committed to public welfare initiatives. In 1998, we launched the inaugural "Chaoju Brightness Action". Since then, the group has collaborated with various levels of government, the Red Cross, disabled persons' federations, charity federations, international philanthropic organizations, and blindness prevention entities to provide free vision restoration assistance for impoverished cataract patients. Concurrently, we have carried out various public welfare projects, including aid for diabetic retinopathy patients, myopia prevention and control among children and adolescents, and rehabilitation training for children with amblyopia. Furthermore, we actively respond to the "Belt and Road" initiative by promoting the "Brightness Journey" public welfare campaign on an international scale.

In 2025, a total of 45 public welfare projects were implemented across 24 hospitals under the group, collectively conducting 285,494 eye health screenings and performing 10,692 free cataract restoration surgeries. Additionally, free rehabilitation training was provided to 509 children with amblyopia, while student myopia screenings were carried out for 2.8146 million individuals across 3,150 schools.

Case Mobile Ophthalmic Surgery Vehicle Project

As a long-term partner of the Asian Foundation for the Prevention of Blindness, Chaoju Eye Care deeply engages in the mobile eye surgery vehicle project. With 38 years of dedicated ophthalmic medical service, our public-welfare footprint spans multiple provinces and regions including Inner Mongolia Autonomous Region, Beijing, Hebei, Shanxi, Zhejiang, Jiangsu, and Ningxia Hui Autonomous Region, extending further to Mongolia. We leverage professional medical expertise to build bridges of care for people in remote and border areas.

Since the launch of the mobile eye surgery vehicle project, Chaoju Eye Care has cumulatively provided vision restoration for over 80,000 patients with eye diseases, established a protective network for the eye health of 3 million children and adolescents, and helped 2,248 children with amblyopia regain clear vision. Furthermore, we have innovatively driven the deep integration of the project with the Belt and Road Initiative, extending Inner Mongolia's blindness prevention experience and compassionate efforts to neighbouring countries. To date, we have performed free vision-restoring surgeries for 791 patients in Mongolia and trained over 30 local ophthalmologists. Through medical services, we have built a bridge of people-to-people connectivity between China and Mongolia, for which we were honoured with an award presented by the Government of Mongolia.



In 2025, the "Restoring Vision No. 24" mobile surgical unit operated by Chaoju Eye Care achieved the highest number of surgeries performed, and was awarded the Outstanding Contribution Award by the Asian Foundation for the Prevention of Blindness.

Case "Great Love in the North, Dream of Health" project

Under the overall coordination and deployment of the Inner Mongolia Autonomous Region Disabled Persons' Federation, the "Great Love in the North, Dream of Health" cataract assistance project has been steadily advanced across border banners (counties, cities, districts) and ethnic minority communities in the region. Professional medical teams were formed from the Group's hospitals in Baotou, Hulunbuir, Tongliao and Ningxia, equipped with mobile cataract screening and surgery vehicles, to carry out work in 20 border banners. To date, through meticulous screening and evaluation, eligible patients have been accurately identified, and 1,964 free cataract surgeries have been completed.





Case "Golden Vision, Love in Double Ninth Festival" public welfare event

During the Double Ninth Festival, all hospitals under Chaoju Eye Care simultaneously carried out the public welfare free consultation activity themed "Golden Vision, Love in Double Ninth Festival", going deep into elderly-centric locations such as townships, communities, and neighbourhoods to provide free eye health screening services and professional eye care guidance for the elderly. Through practical actions, we brought additional warmth to the Double Ninth Festival.



Enhancing Ophthalmic Diagnosis and Treatment Capacity Development

The Group actively promotes the accessibility of ophthalmic medical services. While expanding its diagnostic and treatment network, it fully leverages its resources and strengths in the field of ophthalmology to provide professional ophthalmic training for countries or regions where medical resources require enhancement. This helps improve the professional skills of ophthalmologists and related practitioners, enabling more patients to access convenient and high-quality diagnostic and treatment services.

Case 2025 "Belt and Road·Bright Journey" Mongolia Action Optometry Training Course

In 2019, the "Belt and Road·Bright Journey" Mongolia Project was officially launched as one of the commemorative events marking the 70th anniversary of the establishment of diplomatic relations between China and Mongolia. The "Mongolian Optometry Training Program" was jointly initiated by the Red Cross Society of Inner Mongolia Autonomous Region, the Mongolian Red Cross Society, Chaoju Eye Care, and Wenzhou Medical University. It aims to promote bilateral cooperation in the field of optometry between China and Mongolia, further deepen the humanitarian collaboration between the two Red Cross societies, and contribute China's expertise and solutions to ophthalmic healthcare in Mongolia.

In 2025, the Phase III of Mongolian ophthalmologists underwent a three-week training programme at Chaoju (Inner Mongolia) Eye Hospital, followed by a one-week study session in Wenzhou. Through theoretical learning, workshops, clinical practice, case analysis, and visits to China Eye Valley (Eye Health Industry Innovation Base) and the Eye Health Science Popularization Museum, they further refined their foundational optometric theory and skills, learned the latest clinical and research advances in optometry in China, and deepened their understanding of the principles and concepts of optometric medicine.



Case Dalat Banner Ophthalmic Disease Diagnosis and Treatment Enhancement Training Course

To enhance the diagnosis and treatment capabilities for ophthalmic diseases in Dalat Banner and strengthen the construction of ophthalmic medical talent, in October 2025, Chaoju (Dalat) Eye Hospital hosted the Dalat Banner Ophthalmic Disease Diagnosis and Treatment Enhancement Training Course. The course invited relevant professionals from all medical institutions within Dalat Banner to participate. Through specialised lectures, case discussions, and other formats, it aimed to build a professional communication platform and promote the sharing of regional medical resources and collaborative development.



Case 2025 Chaoju Cup Xiangshan County Ophthalmologists Academic Salon

In September 2025, Xiangshan Hospital hosted the Sixth Xiangshan County Chaoju Cup Ophthalmologists Academic Salon, inviting ophthalmologists from medical institutions across the county. The event focused on in-depth discussions and sharing around clinical research achievements in complex eye diseases, cutting-edge diagnostic and treatment technologies, intricate case analysis, and key points in myopia prevention and control, among other topics. Through annual hosting of ophthalmic academic salons, we collaborate with peers across the county to contribute to the vigorous development of ophthalmology in Xiangshan County.



Eye Health Knowledge Dissemination

The Group continues to deepen its efforts in eye health knowledge dissemination and public welfare services, committed to protecting the visual health of the public with professional expertise, allowing clear and bright vision to illuminate everyone's lives. This year, the science education video from the Chaoju Eye Care Eye Health Science Exhibition Hall won the third prize in the National Eye Health Science Education Competition, and Tangshan Jidong Hospital established Tangshan City's first youth myopia prevention and control science education base.

Case Chaoju Eye Care "Love Your Eyes" Day

To commemorate the 30th National "Love Your Eyes" Day and actively respond to the National Health Commission's call to "Focus on Universal Eye Health", we carried out a series of diverse activities during the event period.

During the Children's Day and "Love Your Eyes" Day period, hospitals under Chaoju Eye Care focused on preventing and controlling myopia in children and adolescents, launching special educational activities such as "Little Doctor" vocational experience programs at Chaoju Eye Care, visits to the Eye Health Science Exhibition Hall, ophthalmic knowledge dissemination lectures, and parent-child interactive activities. Through immersive interactions, children can intuitively experience the wonder of vision, and "protecting eyesight" is transformed from an abstract concept into concrete cognition. All departments also actively carried out live streams related to the theme of Eye Care Day, offering in-depth yet accessible explanations on high-incidence eye diseases across different age groups, the prevention and control of myopia in children and adolescents, as well as common eye-related hot topics. They also provided real-time online Q&A sessions, efficiently delivering professional eye health knowledge to a broader audience.









Case National Myopia Prevention and Control Publicity and Education Month Activity

In March and September 2025, which are designated as the National Myopia Prevention and Control Publicity and Education Month, the group adopted the themes "Act Early, Target Small, Focus on Key Aspects to Reduce Myopia Rates Faster – A New Semester, Brighter Eyes" and "Protect Children's Farsightedness Reserve Amount to Prevent and Reduce Myopia." Through initiatives such as the " Baibian Dayanmeng" painting activity, professional experiences as a junior ophthalmologist at Chaoju Eye Care, research visits to eye health science museums, online science livestreams, school screenings, and offline lectures, the group aimed to enhance children's and parents' awareness of eye health and promote the importance of caring for and protecting their eyes.



Case The First Eye Care Cultural Activity in 2025

Inner Mongolia Chaoju Hospital successfully held the inaugural "Tea and Health" Eye Care Cultural Tea Appreciation Event. Through a series of activities including seasonal eye health lectures, tea art performances, tea ceremony etiquette demonstrations, tea serving, brewing experiences, and tea tasting, the event invited nearly 50 members from the Retinal Diseases Department and Traditional Chinese Medicine Ophthalmology Department to participate. This event enabled the attending members to gain an in-depth understanding of standardized ophthalmic diagnosis and treatment, effectively enhancing their sense of fulfillment and happiness as consumers. At the same time, it also allowed all participants to fully appreciate Chaoju Eye Care's cultural commitment to safeguarding patients' visual health and promoting scientifically informed eye care practices.



Annex I: Quantitative ESG Data Table

Economic Performance

Performance Indicators	Unit	2023	2024	2025
Operating revenue	RMB 1,000	1,369,505	1,405,454	1,360,360
Charitable donation amount	RMB 10,000	1,613.40	410.00	340.00

Governance Performance

	Performance Indicators	Unit	2023	2024	2025
Business Ethics	Percentage of board of directors' members covered by anticorruption training[1]	%	100	100	100
	Number of corruption lawsuits filed against and resolved for the issuer or its employees during the Reporting Period	pcs	0	0	0
	Number of illegal or non-compliant incidents in market promotion (including advertising, sales, and sponsorship)[2]	pcs	/	0	1

Note 1: Calculation formula: Percentage of Board of directors' members covered by anti-corruption training = Number of board members receiving anti-corruption training / Total number of board members × 100%.

Note 2: For specific details, please refer to the government website: https://app.gjzwfw.gov.cn/jmopen/webapp/html5/xzcfjdxxpc/index.html

Environmental Performance

	Performance Indicators	Unit	2023	2024	2025
Environmental Management	Number of incidents penalized for violating environmental protection laws and regulations	pcs	0	0	0
Energy Management	Purchased electricity consumption	MWh	10,218.23	8,703.84	9,060.64
	Intensity of purchased electricity consumption	MWh /RMB 10,000	0.075	0.52	0.07
	Total natural gas consumption	m^3	45,275.80	61,114.59	136,703.59[4]
	Natural gas consumption intensity	m^3/RMB 10,000	0.33	0.43	1.00
	Gasoline consumption	Liters	227,073.16	219,430.69	189,903.07
	Gasoline consumption intensity	Liters/RMB 10,000	1.66	1.56	1.40
	Diesel consumption	Liters	99,869.84	97,460.78	77,819.98
	Diesel consumption intensity	Liters/RMB 10,000	0.73	0.70	0.57
Water Resource Management	Total water consumption	m^3	119,373.30	120,643.60	103,550.84
	Water consumption intensity	m^3/RMB 10,000	0.87	0.86	0.76
Packaging material management	Usage of packaging materials for finished products[2]	tons	22.23	22.00	1[3]
	Usage of packaging materials for finished products per RMB 10,000 of revenue	tons/RMB 10,000	0.00016	0.0002	0.000007
Emissions Management[5]	Medical wastewater discharge	m^3	26,000.33	21,925.40	23,070.07
	Domestic wastewater discharge	m^3	76,684.65	76,253.53	71,771.39
Waste Management	Non-hazardous waste generation	tons	577.40	540.35	694.75
	Non-hazardous waste generation per 10,000 RMB of revenue	tons/RMB 10,000	0.0042	0.0038	0.005
	Hazardous waste generation	tons	159.21	134.92	125.47
	Hazardous waste generation per 10,000 RMB of revenue	tons/RMB 10,000	0.0012	0.0010	0.0009

	Performance Indicators	Unit	2023	2024	2025
GHG emissions	Direct Greenhouse Gas Emissions (Scope 1)[6]	Tons CO_2e	866.54	811.78	846.78
	Indirect greenhouse gas emissions (Scope 2)[6]	Tons CO_2e	5,827.46	4,670.48	4,807.58
	Indirect greenhouse gas emissions (Scope 3)[7]	Tons CO_2e	/	/	2244.40
	Employee commuting	Tons CO_2e	/	/	473.50
	Business travel	Tons CO_2e	/	/	418.97
	Fuel- and energy-related activities	Tons CO_2e	/	/	1,351.93
	Total amount of GHG emissions (Scope 1 and Scope 2)	Tons CO_2e	6,694.00	5,482.25	5,653.35
	Greenhouse gas emissions (Scope 1 and 2) per 10,000 RMB of revenue	Tons CO_2e/RMB 10,000	0.049	0.039	0.041

Note 1: In 2025, the scope of environmental performance coverage has expanded from 30 ophthalmic hospitals in the previous year to 31 ophthalmic hospitals and 18 optometry centers. We reviewed and standardized the indicator definitions, and made retrospective adjustments to certain 2024 data accordingly.

Note 2: Only Baotou Hospital is involved in drug production, so the total amount of usage of packaging materials for finished products mainly covers Baotou Hospital.

Note 3: In 2025, the relocation of the preparation room at Baotou Hospital led to a decline in production capacity.

Note 4: In 2025, Chengde and other hospitals began using natural gas boilers.

Note 5: Nitrogen oxides, sulfur dioxide, particulate matter and other waste gases were classified as unimportant indicators, considering their low relevance to the Group's main business and the relatively small quantities of nitrogen oxides, sulfur dioxide, particulate matter and other waste gases produced by the Group annually.

Note 6: Chaoju Eye Care measures and discloses its greenhouse gas emissions in accordance with the *Greenhouse Gas Protocol: Corporate Accounting and Reporting Standard (2004)* (GHG Protocol). Greenhouse gas inventory of Chaoju Eye Care includes carbon dioxide, methane, and nitrous oxide, primarily derived from gasoline, diesel, natural gas, and purchased electricity. Greenhouse gas accounting is presented in carbon dioxide equivalent, with carbon emissions from electricity calculated based on the *2023 Baseline Emission Factors for Regional Grids in China for Emission Reduction Projects* issued by the Ministry of Ecology and Environment, and carbon emissions from other energy sources calculated according to publications such as the *IPCC 2006 Guidelines for National Greenhouse Gas Inventories (2019 Revision)* issued by the Intergovernmental Panel on Climate Change (IPCC).

Note 7: Scope 3 Greenhouse Gases: Includes greenhouse gas emissions from employee commuting, business travel and fuel- and energy-related activities. We comprehensively assess and verify the data quality of each category. Measured values are incorporated into the statistical scope when specific activities or business service items can be clearly identified. In cases where measured values are unavailable, calculations are completed using scientifically reasonable estimation methods. In the future, as the underlying data quality for the two Scope 3 greenhouse gas emission categories improves, both the coverage and accuracy of the data will be further enhanced.

Note 8: The minor decimal discrepancies between the sum of Scope 1 and Scope 2 greenhouse gas emissions and the total emissions are considered normal statistical outcomes.

Note 9: The symbol "/" indicates that data for that year was not collected.

Social Performance

	Performance Indicators	Unit	2023	2024	2025
Employee employment	Total number of employees	Person	2,597	2,608	2,590
	Total number of employees by gender – Female employees	Person	1,947	1,973	1,940
	Total number of employees by gender – Male employees	Person	650	635	650
	Total number of employees by rank – Grassroots employees	Person	2,254	2,261	2,186
	Total number of employees by rank – Mid-level management employees	Person	342	342	399
	Total number of employees by rank – High-level management employees	Person	5	5	5
	Total number of employees by form of employment – Full-time contract employees	Person	2,543	2,543	2,535
	Total number of employees by form of employment – Full-time dispatched employees	Person	6	6	1
	Total number of employees by form of employment – Part-time employees	Person	59	59	54
	Total number of employees by age group – Under 30 years old employees	Person	825	825	694
	Total number of employees by age group – 30-50 years old employees	Person	1,550	1,550	1,612
	Total number of employees by age group – Over 50 years old employees	Person	259	233	284
	Total number of employees by region – Mainland China employees	Person	2,592	2,603	2,585
	Total number of employees by region – Hong Kong, Macau, Taiwan, and Overseas Regions employees	Person	5	5	5
	Employee turnover rate	%	8.51	10.70	14.79
	Employee turnover rate by gender[1] – Female employees	%	6.15	12.28	14.38
	Employee turnover rate by gender[1] – Male employees	%	9.30	10.19	16.00
	Employee turnover rate by age group – Under 30 years old employees	%	15.05	14.30	22.48
	Employee turnover rate by age group – 30-50 years old employees	%	5.36	8.45	10.05
	Employee turnover rate by age group – Over 50 years old employees	%	4.63	12.88	22.89
	Employee turnover rate by region – Mainland China employees	%	8.53	10.72	14.97
	Employee turnover rate by region – Hong Kong, Macau, Taiwan, and Overseas Regions employees	%	0.00	0.00	0.00

Performance Indicators		Unit	2023	2024	2025
Human Capital Development	Coverage of employees receiving training	%	100	100	100
	Percentage of employees receiving training by gender[2] – Female employees	%	100	100	100
	Percentage of employees receiving training by gender[2] – Male employees	%	100	100	100
	Percentage of employees receiving training by rank[2] – Grassroots employees	%	100	100	100
	Percentage of employees receiving training by rank – Mid-level management employees	%	100	100	100
	Percentage of employees receiving training by rank – High-level management employees	%	100	100	100
	Training hours per employee	Hours	43.33	66.64	81.09
	Average training hours per employee by gender[3] – Female employees	Hours	43.18	67.33	78.27
	Average training hours per employee by gender[3] – Male employees	Hours	39.88	64.50	90.00
	Average training hours per employee by rank[3] – Grassroots employees	Hours	46.84	63.23	79.00
	Average training hours per employee by rank[3] – Mid-level management employees	Hours	12.46	88.64	90.00
	Average training hours per employee by rank[3] – High-level management employees	Hours	72.00	104.00	128.00
Occupational Health and Safety	Number of work-related fatalities	Person	0	0	0
	Percentage of work-related fatalities	%	0	0	0
	Number of workdays lost due to work-related injuries	Days	0	90	0
	Number of penalties imposed for violations of employee employment and labour laws and regulations	pcs	0	0	0
Medical Service Management	Number of complaints received about products and services	pcs	85	75	63
	Complaint handling rate	%	100	100	100
Supplier Management	Total number of suppliers	Number	296	1,035	1,060
	Number of suppliers by region – Mainland China region	Number	286	1,030	1054
	Number of suppliers by region – Hong Kong, Macau, Taiwan, and Overseas Regions	Number	10	5	6

Note 1: Employee Turnover Rate of a particular category = Number of employees lost in this category / Number of employees in this category × 100%.

Note 2: Coverage of employees trained of a particular category = Number of employees trained in this category / Number of employees in this category × 100%.

Note 3: Average training hours of employees of a particular category = Total training hours of employees in this category / Number of employees in this category.

Annex II: Index Table of The Hong Kong Stock Exchange's ESG Reporting Code

Mandatory Disclosure Requirements	Section
Governance Structure	
A statement from the board containing the following elements: • (i) a disclosure of the board's oversight of ESG issues; • (ii) the board's ESG management approach and strategy, including the process used to evaluate, prioritise and manage material ESG-related issues (including risks to the issuer's businesses); and • (iii) how the board reviews progress made against ESG-related goals and targets with an explanation of how they relate to the issuer's businesses.	About This Report Board Statement
Reporting Principles	
A description of, or an explanation on, the application of the following Reporting Principles in the preparation of the ESG report: • **Materiality:** The ESG report should disclose: (i) the process to identify and the criteria for the selection of material ESG factors; (ii) if a stakeholder engagement is conducted, a description of significant stakeholders identified, and the process and results of the issuer's stakeholder engagement. • **Quantitative:** Information on the standards, methodologies, assumptions and/ or calculation tools used, and source of conversion factors used, for the reporting of emissions/energy consumption (where applicable) should be disclosed. • **Consistency:** The issuer should disclose in the ESG report any changes to the methods or KPIs used, or any other relevant factors affecting a meaningful comparison.	About This Report Report Preparation Principles
Reporting Boundary	
A narrative explaining the reporting boundaries of the ESG report and describing the process used to identify which entities or operations are included in the ESG report. If there is a change in the scope, the issuer should explain the difference and reason for the change.	About This Report Scope of the Report

"Comply or explain" Provisions		
Subject Areas, Aspects, General Disclosures and KPIs		**Section**
A *Environmental*		
Aspect A1: Emissions		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to air, discharges into water and land, and generation of hazardous and non-hazardous waste.	Cherishing the Environment and Fostering Green Development Emissions Management
KPI A1.1	The types of emissions and respective emissions data.	Cherishing the Environment and Fostering Green Development Emissions Management Annex I: Quantitative ESG Data Table Environmental Performance
KPI A1.3	Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Annex I: Quantitative ESG Data Table Environmental Performance
KPI A1.4	Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Annex I: Quantitative ESG Data Table Environmental Performance
KPI A1.5	Description of emission target(s) set and steps taken to achieve them.	Cherishing the Environment and Fostering Green Development Emissions Management
KPI A1.6	Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.	Cherishing the Environment and Fostering Green Development Emissions Management
Aspect A2: Use of Resources		
General Disclosure	Policies on the efficient use of resources, including energy, water and other raw materials.	Cherishing the Environment and Fostering Green Development Resource Management
KPI A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).	Annex I: Quantitative ESG Data Table Environmental Performance
KPI A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility).	Annex I: Quantitative ESG Data Table Environmental Performance
KPI A2.3	Description of energy use efficiency target(s) set and steps taken to achieve them.	Cherishing the Environment and Fostering Green Development Resource Management
KPI A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.	Cherishing the Environment and Fostering Green Development Water Resource Management
KPI A2.5	Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.	Annex I: Quantitative ESG Data Table Environmental Performance
Aspect A3: The Environment and Natural Resources		
General Disclosure	Policies on minimising the issuer's significant impacts on the environment and natural resources.	Cherishing the Environment and Fostering Green Development Water Resource Management Emissions Management Climate Change Response
KPI A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them	
B *Social*		
Employment and Labour Practice		
Aspect B1: Employment		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare.	Prioritising Employees and Cultivating a Harmonious Workplace Employee Employment
KPI B1.1	Total workforce by gender, employment type (for example, full- or parttime), age group and geographical region.	Annex I: Quantitative ESG Data Table Social Performance
KPI B1.2	Employee turnover rate by gender, age group and geographical region.	Annex I: Quantitative ESG Data Table Social Performance
Aspect B2: Health and Safety		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to providing a safe working environment and protecting employees from occupational hazards.	Prioritising Employees and Cultivating a Harmonious Workplace Occupational Health and Work Safety
KPI B2.1	Number and rate of work-related fatalities occurred in each of the past three years including the reporting year.	Annex I: Quantitative ESG Data Table Social Performance
KPI B2.2	Lost days due to work injury.	Annex I: Quantitative ESG Data Table Social Performance
KPI B2.3	Description of occupational health and safety measures adopted, and how they are implemented and monitored.	Prioritising Employees and Cultivating a Harmonious Workplace Occupational Health and Work Safety
Aspect B3: Development and Training		

"Comply or explain" Provisions		
Subject Areas, Aspects, General Disclosures and KPIs		**Section**
General Disclosure	Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities.	Prioritising Employees and Cultivating a Harmonious Workplace Employee Training
KPI B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle management).	Annex I: Quantitative ESG Data Table Social Performance
KPI B3.2	The average training hours completed per employee by gender and employee category.	Annex I: Quantitative ESG Data Table Social Performance
Aspect B4: Labour Standards		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child and forced labour.	Prioritising Employees and Cultivating a Harmonious Workplace Employee Employment
KPI B4.1	Description of measures to review employment practices to avoid child and forced labour.	
KPI B4.2	Description of steps taken to eliminate such practices when discovered.	
Operating Practices		
Aspect B5: Supply Chain Management		
General Disclosure	Policies on managing environmental and social risks of the supply chain.	Upholding Responsibility to Achieve Stable Operations Supply Chain Management
KPI B5.1	Number of suppliers by geographical region.	Annex I: Quantitative ESG Data Table Social Performance
KPI B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.	Upholding Responsibility to Achieve Stable Operations Supply Chain Management
KPI B5.3	Description of practices used to identify environmental and social risks along the supply chain, and how they are implemented and monitored.	Upholding Responsibility to Achieve Stable Operations Supply Chain Management
KPI B5.4	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored.	Upholding Responsibility to Achieve Stable Operations Supply Chain Management
Aspect B6: Product Responsibility		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress.	Serving Patients and Improving Medical Quality Medical Quality Management Assurance of Medical Safety Medical Service Management Pharmaceutical Quality Management
KPI B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons.	Serving Patients and Improving Medical Quality Pharmaceutical Quality Management
KPI B6.2	Number of products and service related complaints received and how they are dealt with.	Annex I: Quantitative ESG Data Table Social Performance Serving Patients and Improving Medical Quality Medical Service Management
KPI B6.3	Description of practices relating to observing and protecting intellectual property rights.	Serving Patients and Improving Medical Quality Scientific Research and Innovation
KPI B6.4	Description of quality assurance process and recall procedures.	Serving Patients and Improving Medical Quality Pharmaceutical Quality Management
KPI B6.5	Description of consumer data protection and privacy policies, and how they are implemented and monitored.	Upholding Responsibility to Achieve Stable Operations Information Security and Patient Privacy Protection
Aspect B7: Anti-corruption		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.	Standardized Operation and Strengthened Corporate Governance Business Ethics Annex I: Quantitative ESG Data Table Governance Performance
KPI B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the Reporting Period and the outcomes of the cases.	
KPI B7.2	Description of preventive measures and whistle-blowing procedures, and how they are implemented and monitored.	
KPI B7.3	Description of anti-corruption training provided to directors and staff.	
Community		
Aspect B8: Community Investment		
General Disclosure	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests.	Passing Love and Engaging in Charitable Actions Volunteer medical consultation and vision screening Enhancing ophthalmic diagnosis and treatment capacity development Eye health knowledge dissemination Annex I: Quantitative ESG Data Table Economic Performance
KPI B8.1	Focus areas of contribution (e.g. education, environmental concerns, labour needs, health, culture, sport).	
KPI B8.2	Resources contributed (e.g. money or time) to the focus area.	

Disclosure Obligation		Section
Governance		
Governance	19. An issuer shall disclose information about: (a) the governance body(s) (which can include a board, committee or equivalent body charged with governance) or individual(s) responsible for oversight of climate-related risks and opportunities. (b) management's role in the governance processes, controls and procedures used to monitor, manage and oversee climate-related risks and opportunities	Climate Change Response-Governance Climate-related considerations have not yet been incorporated into the compensation policy.
Strategy		
Climate-related risks and opportunities	20. An issuer shall disclose information to enable an understanding of climate-related risks and opportunities that could reasonably be expected to affect the issuer's cash flows, its access to finance or cost of capital over the short, medium or long term. Specifically, the issuer shall: (a) describe climate-related risks and opportunities that could reasonably be expected to affect the issuer's cash flows, its access to finance or cost of capital over the short, medium or long term; (b) explain, for each climate-related risk the issuer has identified, whether the issuer considers the risk to be a climate-related physical risk or climate-related transition risk; (c) specify, for each climate-related risk and opportunity the issuer has identified, over which time horizons – short, medium or long term – the effects of each climate-related risk and opportunity could reasonably be expected to occur; and (d) explain how the issuer defines 'short term', 'medium term' and 'long term' and how these definitions are linked to the planning horizons used by the issuer for strategic decision-making.	Climate Change Response-Strategy
Business model and value chain	21. An issuer shall disclose information that enables an understanding of the current and anticipated effects of climate-related risks and opportunities on the issuer's business model and value chain. Specifically, the issuer shall disclose: (a) a description of the current and anticipated effects of climate-related risks and opportunities on the issuer's business model and value chain; and (b) a description of where in the issuer's business model and value chain climate-related risks and opportunities are concentrated (for example, geographical areas, facilities and types of assets).	Climate Change Response-Strategy
Strategy and decision-making	22. An issuer shall disclose information that enables an understanding of the effects of climate-related risks and opportunities on its strategy and decision-making. Specifically, the issuer shall disclose: (a) information about how the issuer has responded to, and plans to respond to, climate-related risks and opportunities in its strategy and decision-making, including how the issuer plans to achieve any climate-related targets it has set and any targets it is required to meet by law or regulation. (b) information about how the issuer is resourcing, and plans to resource, the activities disclosed in accordance with paragraph 22(a).	Climate Change Response-Governance The Group currently does not have a climate-related transition plan.
	23. An issuer shall disclose information about the progress of plans disclosed in previous Reporting Periods in accordance with paragraph 22(a).	Climate Change Response-Strategy

Disclosure Obligation		Section
Financial position, financial performance and cash flows	Current financial effect 24. An issuer shall disclose qualitative and quantitative information about: (a) how climate-related risks and opportunities have affected its financial position, financial performance and cash flows for the Reporting Period; and (b) the climate-related risks and opportunities identified in paragraph 24(a) for which there is a significant risk of a material adjustment within the next annual Reporting Period to the carrying amounts of assets and liabilities reported in the related financial statements.	Climate Change Response-Strategy
	Anticipated financial effect 25. The issuer shall provide qualitative and quantitative disclosures about: (a) how the issuer expects its financial position to change over the short, medium and long term, given its strategy to manage climate-related risks and opportunities, taking into consideration: (i) its investment and disposal plans; and (ii) its planned sources of funding to implement its strategy; and (b) how the issuer expects its financial performance and cash flows to change over the short, medium and long term, given its strategy to manage climate-related risks and opportunities.	Climate Change Response-Strategy Due to the immaturity of existing skills, capabilities, and resources, the anticipated financial impact has not been quantified at this stage.
Climate resilience	26. An issuer shall disclose information that enables an understanding of the resilience of the issuer's strategy and business model to climate-related changes, developments and uncertainties, taking into consideration the issuer's identified climate-related risks and opportunities. An issuer shall use climate-related scenario analysis to assess its climate resilience using an approach that is commensurate with an issuer's circumstances. In providing quantitative information, the issuer may disclose a single amount or a range. Specifically, the issuer shall disclose: (a) the issuer's assessment of its climate resilience as at the reporting date; (b) how and when the climate-related scenario analysis was carried out.	Climate Change Response-Strategy
Risk Management		
Risk Management	27. An issuer shall disclose information about: (a) the processes and related policies it uses to identify, assess, prioritise and monitor climate-related risks; (b) the processes the issuer uses to identify, assess, prioritise and monitor climate-related opportunities (including information about whether and how the issuer uses climate-related scenario analysis to inform its identification of climate-related opportunities); and (c) the extent to which, and how, the processes for identifying, assessing, prioritising and monitoring climate-related risks and opportunities are integrated into and inform the issuer's overall risk management process.	Climate Change Response-Risk Management Compared to the previous financial year, there have been no changes in the Group's risk management processes.

Disclosure Obligation		Section
Metrics and Targets		
Greenhouse gas emissions	28. An issuer shall disclose its absolute gross greenhouse gas emissions generated during the Reporting Period, expressed as metric tons of CO_2 equivalent, classified as: (a) Scope 1 greenhouse gas emissions; (b) Scope 2 greenhouse gas emissions; and (c) Scope 3 greenhouse gas emissions.	Annex I-Environmental Performance
	29. An issuer shall: (a) measure its greenhouse gas emissions in accordance with the Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (2004) unless required by a jurisdictional authority or another exchange on which the issuer is listed to use a different method for measuring greenhouse gas emissions; (b) disclose the approach it uses to measure its greenhouse gas emissions; (c) for Scope 2 greenhouse gas emissions disclosed in accordance with paragraph 28(b), disclose its location-based Scope 2 greenhouse gas emissions, and provide information about any contractual instruments that is necessary to enable an understanding of the issuer's Scope 2 greenhouse gas emissions; and (d) for Scope 3 greenhouse gas emissions disclosed in accordance with paragraph 28(c), disclose the categories included within the issuer's measure of Scope 3 greenhouse gas emissions, in accordance with the Scope 3 categories described in the Greenhouse Gas Protocol Corporate Value Chain (Scope 3) Accounting and Reporting Standard (2011).	Annex I-Environmental Performance
Climate-related transition risks	30. An issuer shall disclose the amount and percentage of assets or business activities vulnerable to climate-related transition risks.	After assessment, the Group does not have assets or business activities that are vulnerable to climate-related transition risks.
Climate-related physical risks	31. An issuer shall disclose the amount and percentage of assets or business activities vulnerable to climate-related physical risks.	Climate Change Response-Metrics and Targets
Climate-related opportunities	32. An issuer shall disclose the amount and percentage of assets or business activities aligned with climate-related opportunities.	Climate Change Response-Metrics and Targets
Capital deployment	33. An issuer shall disclose the amount of capital expenditure, financing or investment deployed towards climate-related risks and opportunities.	Climate Change Response-Metrics and Targets
Internal carbon prices	34. An issuer shall disclose: (a) an explanation of whether and how the issuer is applying a carbon price in decisionmaking (for example, investment decisions, transfer pricing, and scenario analysis); and (b) the price of each metric tonne of greenhouse gas emissions the issuer uses to assess the costs of its greenhouse gas emissions; or an appropriate negative statement that the issuer does not apply a carbon price in decision-making.	The Group has not yet applied carbon pricing in its decision-making processes.
Remuneration	35. An issuer shall disclose whether and how climate-related considerations are factored into remuneration policy, or an appropriate negative statement.	Climate-related considerations have not yet been incorporated into the compensation policy.

Disclosure Obligation		Section
Industry-based metrics	36. An issuer is encouraged to disclose industry-based metrics that are associated with one or more particular business models, activities or other common features that characterise participation in an industry	The Group currently does not have specific industry metrics.
Climate-related targets	37. An issuer shall disclose (a) the qualitative and quantitative climate-related targets the issuer has set to monitor progress towards achieving its strategic goals; and (b) any targets the issuer is required to meet by law or regulation, including any greenhouse gas emissions targets. For each target, the issuer shall disclose: (a) the metric used to set the target; (b) the objective of the target (for example, mitigation, adaptation or conformance with science-based initiatives); (c) the part of the issuer to which the target applies (for example, whether the target applies to the issuer in its entirety or only a part of the issuer, such as a specific business unit or geographic region); (d) the period over which the target applies; (e) the base period from which progress is measured; (g) if the target is quantitative, whether the target is an absolute target or an intensity target; and (h) how the latest international agreement on climate change, including jurisdictional commitments that arise from that agreement, has informed the target.	Climate Change Response-Metrics and Targets
	38. An issuer shall disclose information about its approach to setting and reviewing each target, and how it monitors progress against each target, including: (a) whether the target and the methodology for setting the target has been validated by a third party; (b) the issuer's processes for reviewing the target; (c) the metrics used to monitor progress towards reaching the target; and (d) any revisions to the target and an explanation for those revisions.	Climate Change Response-Metrics and Targets
	39. An issuer shall disclose information about its performance against each climate-related target and an analysis of trends or changes in the issuer's performance.	Climate Change Response-Metrics and Targets
	40. For each greenhouse gas emissions target disclosed in accordance with paragraphs 37 to 39, an issuer shall disclose: (a) which greenhouse gases are covered by the target; (b) whether Scope 1, Scope 2 or Scope 3 greenhouse gas emissions are covered by the target; (c) whether the target is a gross greenhouse gas emissions target or a net greenhouse gas emissions target. If the issuer discloses a net greenhouse gas emissions target, the issuer is also required to separately disclose its associated gross greenhouse gas emissions target; (d) whether the target was derived using a sectoral decarbonisation approach; and (e) the issuer's planned use of carbon credits to offset greenhouse gas emissions to achieve any net greenhouse gas emissions target.	Climate Change Response-Metrics and Targets The Company has not adopted industry decarbonization methods to derive greenhouse gas emission targets, and currently has no plans to use carbon credits to offset emissions in order to achieve any net greenhouse gas emission goals.
Applicability of cross-industry metrics and industry-based metrics	41. In preparing disclosures to meet the requirements in paragraphs 21 to 26 and 37 to 38, an issuer shall refer to and consider the applicability of cross-industry metrics and industry-based metrics.	Climate Change Response-Strategy, Metrics and Targets

朝聚眼科

CHAOJU EYE CARE